Dopamine Agonists Modify the Development of Brain D1 and D2 Receptor Responsiveness by Hamdi, Anwar A.
East Tennessee State University
Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations Student Works
May 1990
Dopamine Agonists Modify the Development of
Brain D1 and D2 Receptor Responsiveness
Anwar A. Hamdi
East Tennessee State University
Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Pharmacology Commons
This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State
University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East
Tennessee State University. For more information, please contact digilib@etsu.edu.
Recommended Citation
Hamdi, Anwar A., "Dopamine Agonists Modify the Development of Brain D1 and D2 Receptor Responsiveness" (1990). Electronic
Theses and Dissertations. Paper 2692. https://dc.etsu.edu/etd/2692
INFORMATION TO USERS
The most advanced technology has been used to photograph and 
reproduce this manuscript from the microfilm master. UMI films the 
text directly from the original or copy submitted. Thus, some thesis and 
dissertation copies are in typewriter face, while others may be from any 
type of computer printer.
Hie quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely afreet reproduction.
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a  note will indicate 
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand comer and 
continuing from left to right in photographed in one exposure and is 
included in reduced form at the back of the book.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9" black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly 
to order.
University Microfilms International 
A Bell & Howell Information C om pany  
300  North Z e e b  R oad. Ann Arbor. Ml 48106*1346 USA 
313/761*4700 800/521*0600
Order Number 9025S76
D opam ine agonists m odify th e  developm ent o f b ra in  D 1 an d  D2 
rec ep to r responsiveness
Hamdi, Anwar Abdulraliman, Ph.D.
East Tennessee State University, 1990
UMI
300 N. Zccb Rd.
Ann Arbor, MI 48106
DOPAMINE AGONISTS MODIFY THE DEVELOPMENT 
OF BRAIN D1 AND D2 RECEPTOR RESPONSIVENESS
A Dissertation Presented to 
the Faculty of the Department of Pharmacology 
James H. Quillen College of Medicine 
East Tennessee State University
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 1n Biomedical Science
by
Anwar Hamdl, M.D. 
May, 1990
APPROVAL
This is to certify that the Graduate Committee of
Anwar Hamdi
met on the
27th day of November, 1989
The committee read and examined his thesis, supervised his 
defense of it on an oral examination, and decided to recommend that 
his study be submitted to the Graduate Council and the Associate 
Vice-President for Research and Graduate Studies in partial fulfill' 
ment of the requirements for the degree Doctor of Philosophy in 
Biomedical Science.
Chairman, Graduate Committees
€ ■ C
ssociate Vice-President for ResearchSigned on behalf of 
the Graduate Council
A  
and Dean of Graduate School
li
ABSTRACT
DOPAMINE AGONISTS MODIFY THE DEVELOPMENT 
OF BRAIN D1 AND D2 RECEPTOR RESPONSIVENESS
by
Anwar Hamdi, M.D.
Dopamine (DA) agonist-induced behavioral 
supersensitivity in the adult rat has served as the standard 
model for certain of the motor and behavioral side effects 
associated with long-term exposure to OA agonists in humans. 
The mechanisms relating receptor events with behavior 
mediation, however, remain unclear.
The striatum of rats progresses through a prolonged and 
varied postnatal developmental period. In order to examine 
the relative contribution of D1 and D2 receptor-mediated 
mechanisms to behavioral changes which follow chronic 
dopamine agonist exposure, developing rats were treated 
daily from birth with a D1 agonist, SKF 38393 hydrochloride 
(3.0 mg/kg x 32d, i.p.), or a D2 agonist, LY 171555 
hydrochloride (3.0 mg/kg x 32d, i.p.), and/or 6-OHDA (134 
/<g, i.c.v., at 3 d after birth). Following a drug-free 
interval, behavioral responses to selective DA agonists were 
evaluated.
The results indicate that (1) prolonged LY 171555 
treatments in development produced a supersensitive animal 
model for yawning and eating behaviors. (2) Perioral 
movements of high frequency could be produced by a very low 
dose of the DA D2 antagonist spiroperidol in rats treated 
neonatally with 6-OHDA, thereby providing a useful animal 
model to study tardive dyskinesia. (3) The "priming" 
phenomenon described by Breese and co-workers which was 
thought to be produced by D1 agonists only has been found in 
this study to be produced by a D2 agonist as well. This 
model provides a means for studying specific stereotypic 
behaviors in animals. (4) [3HJSCH 23390 and 
[3H]spiroperldol binding to striatal tissue was not altered 
in rats treated 1n development with specific agonists or 
antagonists for the D1 and D2 receptors. A neonatal 6-OHDA 
lesion did not modify binding in any of the agonist- or 
antagonist-treated groups.
In conclusion, DA D1 and D2 agonist treatments during 
postnatal development are effective means of producing new 
animal models that are potentially useful for studying 
clinical disorders in man.
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CHAPTER 1 
Introduction
Anatomical Review 
Dopamine (DA), a catecholamine, is present as a 
neurochemical in one of the most studied neurotransmitter 
systems in the brain. Until 1958, DA had been thought to be 
only an intermediate precursor of norepinephrine and 
epinephrine synthesis (Carlsson et al., 1958; 1959).
Largely on the basis of the fluorescence histochemical 
procedure (Dahlstrom and Fuxe, 1964} and later 
immunocytochemical procedure, DA-containing nerves were 
mapped in the brain. There are three major dopaminergic 
neuronal systems in the brain (Lader, 1983). These are as 
follows:
1. One group of dopamine-neurons originates in the 
ventral tegmental area and terminates in the 
nucleus accumbens, olfactory tubercle, nucleus 
interstitialis stria terminalis, hypothalamus, 
preoptic area, cingulate cortex, hippocampus, 
central amygdaloid nucleus, lateral septum, 
prefrontal and entorhinal cortices, midbrain, and 
ventromedial neostriatum. This so-called A10 
group is commonly known as the mesolimbocortical 
DA system (Beckstead et al., 1979).
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2. A more lateral group of DA cells, designated 
the A9 or mesostriatal DA system, originates in 
the substantia nigra pars compacts. These neurons 
project mainly to the neostriatum (caudate nucleus 
and putamen), amygdala, nucleus accumbens, bed 
nucleus of the stria terminalis, anteromedial 
cortex, entorhinal area, globus pallidus, sub­
thalamic nucleus, and cingulate cortex.
3. A system consisting of short neurons arising 
mainly in the anterior part of the arcuate nucleus 
and the ventral periventricular nucleus of the 
hypothalamus (A12) terminates in the external 
layer of the median eminence (the tubero- 
infundibular DA system), pars intermedia, and 
neural lobes of the pituitary (tuberohypophyseal 
DA system), and infundibular stalk (Nauta et al., 
1978; Beckstead et al., 1979). Other short 
dopaminergic pathways are the incertohypothalamic, 
which links the hypothalamus and lateral septum, 
and the medullary periventricular nucleus in the 
periaqueductal grey matter.
Proposed Functions Of Dopamine Systems 
The physiology and pharmacology of DA from the 
standpoint of its function as a neurotransmitter or 
modulator in the central nervous system (CNS) has been
established, and it is accepted now that the dopaminergic 
system is involved in:
1. Modulation of a variety of behaviors including: 
ambulation or locomotion (Ungerstedt and 
Arbuthnott, 1970; Pijnenburg et al.f 1976), 
stereotyped behaviors (Creese and Iversen, 1973), 
self-stimulation behavior (Phillips and Fibiger, 
1973), stimulus control behavior (Ho and Huang,
1975), conditioned avoidance responding behavior, 
feeding and drinking (for references see Kostrzewa 
and Jacobowitz, 1974; Kostrzewa, 1989), reward- 
seeking behavior (German and Bowden, 1974; Wise, 
1978), latent inhibition in which prior exposure 
to a stimulus not followed by reinforcement 
retards subsequent conditioning to that stimulus 
(Weiner et al., 1984; 1987; Weiner and Feldon,
1987), as well as mechanisms controlling memory 
consolidation and retention (Routtenberg and 
Holzman, 1973; Major and White, 1978; Coulombe and 
White, 1980; White, 1988).
2. Neuroendocrine function (tuberohypophyseal 
dopaminergic system) including: hypothalamic 
secretion of releasing factors, gonadal secretion 
of steroids, and pituitary secretion of prolactin.
Dopamine Receptors
It is now well established on the basis of biochemical, 
anatomical, pharmacological, and behavioral characteristics 
that brain DA can act on at least two distinct subtypes of 
DA receptors (Kebabian, 1978; Kebabian and Caine, 1979; 
Creese et al., 1983; Stoof and Kebabian, 1984; Onali et al., 
1985; Weiss et al., 1985). The D1 type DA receptor is 
coupled to an adenylate cyclase (AC) such that receptor 
occupancy by an agonist increases cyclic adenosine 3*5'- 
monophosphate (cAMP) formation (Hyttel, 1978). The D2 type 
DA receptor, on the other hand, is either unlinked or linked 
to adenylate cyclase in a negative manner such that receptor 
occupancy by an agonist decreases cAMP formation (Stoof and 
Kebabian, 1981; Onali et al., 1984; Battaglia et al., 1985).
The existence of these two receptors has been supported 
by the identification of agonists and antagonists selective 
for either of these receptors.
Studies Directed Specifically to Dopamine D1 and D2
Receptors
The increasing availability of drugs which act 
selectively on D1 or D2 DA receptors now permits a more 
detailed evaluation of their response to chronic blockade or 
stimulation.
The D2 DA receptors in the CNS have been labeled by 
using the selective D2 antagonist, [3H]spiroperidol (Creese
et al., 1977a; Leysen et al., 1978; Laduron et al., 1978; 
Creese, 1982). These autoradiographic studies show high 
densities of autoradiographic grains in the olfactory 
tubercles, nucleus accumbens, nucleus caudate-putamen, 
lateral septum, zona incerta, nucleus subthalamicus, arcuate 
nucleus, central nucleus of the amygdala, claustrum, 
prelateral and lateral mammillary nuclei of the 
hypothalamus, nucleus of the lateral optic tract, dorsal 
interpeduncular nucleus, ventral tegmentum, substantia 
nigra, superior and inferior colliculi, parts of 
periaqueductal grey, portions of the midline, cerebral 
cortex (Klemm et al., 1979), hippocampus, pineal gland, and 
the cerebellum (Bruinnk and Bischoff, 1986). The most dense 
aggregates are found in the striatum and nucleus accumbens 
(Gehlert and Wamsley, 1984).
D1 DA receptors have been studied by using the non- 
selective radioligands cis-[3H]piflupentixol and cis-(Z)- 
[3H]pifluthixol (Hyttel, 1978; 1981). A newer selective 
antagonist for D1 sites, SCH 23390, the 3-methyl 7-chloro 
analog of SKF 38393, [{R)-(+)-8-chloro-2,3,4,5-tetrahydro-3- 
methyl-5-phenyl-lH-3-benzazepine-7-51] (Iorio et al., 1983; 
Hyttel, 1983), crosses the blood brain barrier and is 
subject to extensive first-pass metabolism (the ID50 of SCH 
23390 given orally is about 100-fold higher than after 
intraperitoneal [i.p.] administration). This novel 
benzazepine exhibits nanomolar potency in inhibiting
dopamine stimulation of striatal adenylate cyclase activity 
(Onali et al., 1984; Plantje et al., 1984; Hyttel, 1984) and 
has a Ki value of approximately 0.5 nM for the striatal D1 
DA receptors (Cross et al., 1983; Hyttel, 1983; Billard et 
al., 1984; Schulz et al., 1984). Treatment with SCH 23390 
(0.50 mg/kg, s.c.) prior to peripheral administration of 
EEDQ (the protein-modifying reagent N-ethoxycarbonyl-2- 
ethoxy-1,2-dihydroquinoline) protects D1 DA receptors from 
irreversible blockade by EEDQ, while neither D2 DA nor S2 
serotonin receptors are protected (Hess and Creese, 1986). 
Commercial [3H]SCH 23390 has a low level of nonspecific 
binding, high specific activity (Billard et al., 1984; 
Andersen et al., 1985), and specifically labels D1 sites 
both in vitro and in vivo (Billard et al., 1984; Schulz et 
al., 1984; 1985; Andersen et al., 1985; Andersen and 
Nielsen, 1986). Autoradiographic studies with [3H]SCH 23390 
show that D1 DA receptors are present in abundance in the 
corpus striatum, olfactory tubercle, nucleus accumbens, 
dorsomedial prefrontal cortex, lateral preoptic area, globus 
pallidus, amygdala, lateral septum, parietal cortex, 
hippocampus, hypothalamus, olfactory bulb, cerebellum, and 
brainstem (Schulz et al., 1985). Very low numbers of D1 
sites are observed in the ventral tegmental area (Dawson et 
al., 1986). Within the nigrostriatal system, D1 sites are 
found only postsynaptically within the striatum (Pilloux et 
al., 1987; 1988) and presynaptically in the substantia nigra
(Altar and Hauser, 1987; Filloux et al., 1988).
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Dopamine Receptor Distribution 
The D1 and D2 DA receptors show different distribution 
and number in the brain, have different neuronal 
localization, and have different molecular size. In 
addition, their number changes with age, after long-term 
neuroleptic treatment, and after 6-hydroxydopamine (6-OHDA) 
lesions. The affinity of both neuroleptics and agonists for 
these receptors is very different.
Quantitatively, it has been hypothesized that there may 
be about four times as many D1 DA receptors as there are D2 
DA sites in the striatum (Leff et al., 1984) and olfactory 
tubercles (Hyttel, 1978). More D1 than D2 sites are also 
found in the nucleus accumbens. The ordered ratio of D1/D2 
sites in the brain is striatum> nucleus accumbens> olfactory 
tubercles.
Function and Interaction of DA D1 and D2 Receptors 
The manner in which D1 and D2 DA receptors interact in 
the brain to carry out their function is still unclear, even 
though intensive studies have been directed toward 
understanding the relative contributions of D1 and D2 
receptor subtypes in mediating physiological and behavioral 
phenomena. Available evidence suggests that D2 systems are 
linked to a particular mode of expression of behavior, such
as stereotypy. D1 receptors mediate a discontinuous, non­
stereotyped activation of behavior characterized by episodes 
of a prominent grooming response interpolated among episodes 
of sniffing with some locomotion and rearing, repetitive 
mouth opening and clonic jaw movements (Rosengarten et al., 
1983; 1986; Kolloy and Waddington, 1984; 1985; 1987; 1988; 
Starr and Starr, 1986; Johansson et al., 1987; Murray and 
Waddington, 1989). D1 systems appear to have a greater role 
in influencing the intensity (enabling) of expression of the 
mode selected by D2 systems, with the full expression of 
dopaminergic behavior requiring concurrent stimulation of 
both receptor subtypes (Molloy et al., 1986; Mashurano and 
Waddington, 1986; Braun and Chase, 1986; Waddington, 1986; 
Arnt et al., 1987).
It is now accepted that D1 and D2 DA receptor-activated 
neuronal systems are not functionally isolated, but interact 
in their modulation of motor function:
1. Catalepsy induced by SCH 23390, a D1 
antagonist, can be prevented by pretreatment with 
selective D2 agonists (Meller et al., 1985).
2. Behavioral effects of the D1 DA receptor 
agonist, SKF 38393, which include non-stereotyped 
sniffing, rearing, and locomotor responses, are 
partially reversed by the D2 DA receptor 
antagonist, metoclopramide (Molloy and Waddington, 
1985).
3. Even though they occurs in unlesioned rats, 
behavioral responses to D2 agonists are not 
antagonized by SCH 23390, and responses to D1 
agonists are insensitive to D2 antagonists in 
animals either lesioned with 6-OHDA or depleted of 
DA by treatment with reserpine or a-methyl-p- 
tyrosine (Arnt, 1985a; 1985b; Arnt and Hyttel, 
1985; Herrera-Marschitz and Ungerstedt, 1985; 
Breese and Mueller, 1985; Breese et al., 1985a,b).
4. D2 DA receptors are not independently 
responsible for mediating effects of non-selective 
DA agonists such as apomorphine. Rather, a 
synergistic interaction between D1 and D2 DA 
receptor-regulated processes appears to be 
essential for the expression of behavioral 
phenomena typically associated with non-selective 
DA agonists. The same is true for increases in 
tonic single unit activity in the globus pallidus, 
evoked by systemic administration of these agents. 
The behavioral or physiological effects induced by 
selective D2 agonists apparently require the 
presence of endogenous DA concurrently stimulating 
the D1 receptors (Walters et al., 1987).
5. SKF 38393 stimulates the release of cAMP from 
superfused striatal tissue slices, and this effect 
is antagonized by LY 141865, a selective D2 DA
receptor agonist (Stoof and Kebabian, 1981).
6. Low doses of spiroperidol induce abnormal 
perioral movements in rats, which can be 
potentiated by SKF 38393 (Rosengarten et al.,
1983; 1986).
7. Yawning induced by selective stimulation of DA 
D2 receptors is eliminated by the DA D1 receptor 
antagonist SCH 23390 (Serra et al., 1987).
8. In the dorsal striatum, the stimulation of DA 
D1 receptors facilitates the release of [3H]GABA, 
while stimulation of DA D2 receptors inhibits 
[3H]GABA release (Girault et al., 1986).
9. DA acting on D1 or on D2 receptors, 
respectively, inhibits or facilitates the 
veratridine-evoked release of cholecystokinin 
(Meyer and Krauss, 1983).
10. DA acting on D1 or on D2 receptors, 
respectively, increases or decreases the 
neurotensin level in striatum (Merchant et al., 
1989).
11. DA acting on D1 or on D2 receptors, 
respectively, decreases or increases the substance 
F level in striatum (Sonsalla et al., 1984).
12. Electroencephalogram (EEG) synchronization and 
sedation, classically associated with neuroleptic 
treatment, does not depend upon the selective
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blockade of either DA D1 or D2 receptors, but 
instead requires concurrent blockade of both 
subtypes of receptors (Bo et al., 1988).
13. In vitro studies have shown that haloperidol, 
at concentrations which appear to be selective for 
DA D2 receptor blockade, increases the release of 
[3H]acetylcholine (ACh) from superfused striatal 
tissue slices (Starke et al., 1983), and SCH 23390 
is capable of inhibiting [3H]ACh release.
Consideration of the functional interaction between D1 
and D2 receptors (Breese and Mueller, 1985; Breese et al.r 
1985a,b; Barone et al., 1986; Carlson et al., 1987) could 
have important implications in disorders such as Parkinson's 
disease and schizophrenia, where stimulation or blockade of 
postsynaptic DA receptors confers symptomatic benefit, and 
where the ratio of D1 to D2 receptor blockade may be an 
important determinant of drug action on functions mediated 
by these receptor subtypes.
6-OHDA and Dopamine Receptors 
The specific catecholamine neurotoxin 6-OHDA produces a 
selective permanent destruction of catecholamine cell bodies 
and axon terminals in the brain (Ungerstedt, 1971; Uretsky 
and Iversen, 1970; Kostrzewa and Jacobowitz, 1974). In 
adult rats, the destruction of DA nigrostriatal fibers is 
associated with specific motor behavior dysfunctions; i.e.,
aphagia, adipsia, decreased body weight, akinesia (lower 
level of spontaneous exploratory activity), lack of self- 
grooming (Breese and Traylor, 1970; Evetts et al., 1970; 
Creese and Iversen, 1973), increase in the striatal DA 
receptors (Creese et al., 1977; Creese and Snyder, 1979; 
Breese et al., 1984), and hypermotility and oral stereotypy 
with a challenge dose of either D1 or D2 selective agonists 
(Arnt, 1985b).
While 6-0HDA treatment of neonates produces a nearly 
complete loss of brain catecholamines (Breese and Traylor, 
1972), impairment in food intake is less than that seen in 
an adult lesioned rat.
6-0HDA produces profound and permanent destructive 
effects, especially on the DA efferents arising from A9. 
This is evidenced by a near-complete loss of tyrosine 
hydroxylase (TH), the rate-limiting enzyme in the DA 
synthesis; a loss of TH-immunoreactive fibers in the 
striatum and cell bodies in the substantia nigra pars 
compacts; also a failure of intrastriatal horse radish 
peroxidase (HRP) injections to label cells within the 
substantia nigra. A 2 to 3-fold increase in the amount of 
striatal serotonin (5-HT) is detected at 2-5 months after 
neonatal 6-0HDA treatment of rats (Stachowiak et al., 1984; 
Breese et al., 1984). This effect is accompanied by a 
parallel increase in the uptake of [3H]5-HT into 
synaptosomes prepared from striatum (Stachowiak et al.,
1984) and an enlargement of the serotonergic projections 
from the raphe nucleus to the striatum, especially prominent 
within the rostral striatum (Berger et al., 1985; Snyder et 
al., 1986). Since DA- and 5-HT-containing neurons have 
similar effects on striatal interneurons (Davies and 
Tongroach, 1978), it will become clear why neonatal 6-OHDA 
treatment of rats could have some behavioral sparing. 
Permanent supersensitive behavioral responses to 
dopaminergic agonists, particularly the D1 receptor 
agonists, occur in these rats when observed as adults. The 
Dl-induced behavioral responses include taffy pulling and 
self-mutilatory behaviors. Biochemically there is an 
inability to up-regulate D1 and D2 receptors in response to 
challenge doses of the respective antagonists in adults, 
suggesting that neurochemical adaptation occurs after 
neonatal 6-OHDA lesions, interfering with the capacity of 
specific antagonists to increase the respective DA receptor 
density (Duncan et al., 1987). Neonatally lesioned rats are 
subsensitive to the immobility effect typically produced by 
both DA D1 and D2 antagonists in rats lesioned as adults 
(Duncan et al., 1987). Rats that receive 6-OHDA lesions as 
adults do not show a progressive increase in response to 
repeated administration of DA D1 agonist, SKF 38393, as do 
the neonatally lesioned rats (Criswell et al., 1989). Also, 
there is no change in binding of [3H]SCH 23390 and 
[3H]spiroperidol to rat striatum and nucleus accumbens in
14
adulthood (Breese et al., 1984; 1985a,b; 1986; Duncan et 
al., 1987).
From the above it can be seen that the 6-OHDA lesions 
of neonatal rats produce a model characterized by DA D1 and 
D2 receptor supersensitivity in the absence of a change in 
receptor number.
Disturbances Of The Dopamine Systems In Human CNS
Several serious disorders are known to be related to 
disturbances in the function of the dopaminergic systems in 
the brain.
Parkinson's disease is associated with a loss of the A9 
DA system (Hornykiewicz, 1966). Long term neuroleptic- 
treatment is associated with extrapyramidal side effects, 
including tardive dyskinesia (TD). Huntington's chorea and 
Gilles de la Tourette syndrome are characterized by 
progressive chorea, cognitive impairment, and emotional 
disturbance. These latter disturbances have been attributed 
to an increase in DA transmission (Butler et al., 1979; 
Baldessarini and Tarsy, 1980; Spokes, 1980; 1981; Marsden, 
1982). The mesolimbocortical A10 DA system has been 
implicated in the pathophysiology of schizophrenia. Either 
excessive release of DA or altered receptor sensitivity has 
been implicated in the symptomatology of schizophrenia, 
which is treated with dopaminergic drugs (Matthysse, 1973; 
Stevens, 1973; Snyder, 1982; Chiodo and Bunney, 1983; White
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and Wang, 1983a,b}.
A complete understanding of the pathophysiologic role 
played by DA in such conditions is not possible without a 
knowledge of the development of the receptors which 
represent transducers of the signals generated by this 
neurotransmitter.
Antipsvchotics and Dopamine Receptors 
Antipsychotics or neuroleptics are the drugs of choice 
in the treatment of psychosis and other forms of 
schizophrenia. This class has also been used to treat the 
dystonia symptoms of Huntington's chorea and Gilles de la 
Tourette syndrome (Shapiro et al., 1978).
Using [3H]Haloperidol, an antipsychotic drug, and 
[3H]DA, Seeman et al. (1975; 1976) have provided the first 
direct evidence that neuroleptics compete with DA for 
stereospecific DA binding sites. The relative affinity for 
D2 sites is directly proportional to clinical potency.
Considerable evidence indicates that long term 
treatment with haloperidol results in the development of DA 
receptor supersensitivity. This is manifest as an enhanced 
behavioral response to DA agonists (Gianutsos et al., 1974; 
Bhargava and Ritzmann, 1980) and an increased number of 
[3H]neuroleptic/dopamine receptor binding sites (up- 
regulation) in the striatum (Burt et al., 1976; Muller and 
Seeman, 1977; Matwyshyn and Bhargava, 1983; Mackenzie and
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Zigmond, 1985). The major side effect, tardive dyskinesia, 
which gradually develops in approximately 25% of 
schizophrenics receiving chronic neuroleptics, is 
characterized by uncontrollable purposeless and persistent 
movements of the mouth, tongue, and extremities 
(Baldessarini and Tarsy, 1980). This resembles the 
involuntary movements occurring in Parkinsonian patients 
treated with L-DOPA, and can be reduced either by lowering 
or raising the neuroleptic dose. The proliferation of 
neuroleptic/dopamine binding sites is observed after long 
term administration of either butyrophenones or 
phenothiazines (Clow et al., 1979; Wan et al,, 1983).
Ontogeny of Dopaminergic Neurons 
There is a progressive increase in the striatal 
concentration of DA and associated synthetic enzymes, such 
as TH, DA-stimulated AC, which at birth, represent only 20% 
of adult levels. TH and AC attain adult levels by the age 
of 3 to 4 weeks of postnatal life (Coyle and Axelrod, 1972; 
Coyle and Compochiaro, 1976), and this has been attributed 
to the proliferation and growth of axon terminals (Loizou 
and Salt, 1970; Coyle and Axelrod, 1972). Functional 
dopaminergic-cholinergic interaction does not occur until 
the second week of postnatal life (Coyle and Campiochiaro,
1976). There is no spontaneous single unit activity of 
striatal cells in eight-day-old rat pups. At 17 days
striatal single unit activity is substantially less diverse 
and of a lower frequency than that observed at 28 days. 
Haloperidol induces single unit activity of striatal cells 
at 28 days, but not at 17 days (Napier et al., 1985). 
Haloperidol induces a cataleptic response in 21 days rats, 
but not in a 14 days rats (Coyle et al., 1985). The growth 
of 5-HT axons into the striatum begins late in development 
(Lidov and Molliver, 1982) in comparison to the 5-HT 
innervation of other structures and DA innervation of the 
striatum (Specht et al., 1981). Marked stereotypy to 
apomorphine only appears at 21 days of age. Before that, 
the response is weak and variable. Islands of dopaminergic 
innervation, present in the striatum on day 5, nearly 
disappear by day 15 (Olson et al., 1972). In contrast, the 
DA receptors appear in a uniform pattern beneath the corpus 
callosum. This patch extends further into the striatum and 
is not as elongated as the fluorescent subcallosal streak. 
Receptors then diminish medially and there are no islands of 
receptors to correspond to the fluorescence (Murrin, 1982). 
Neuronal cell division in the striatum is mostly complete 
after the first few postnatal days in the rat (Das and 
Altman, 1970), and there is some evidence for neuronal cell 
death in the first two postnatal weeks, based on estimates 
of the total number of neurons present in the striatum 
(Fentress et al., 1981). At the first day after birth, the 
rat striatum contains only 12 and 24% of the adult level of
18
DA and DOPAC, respectively. The striatal DA content 
increases somewhat slowly thereafter, reaching adult levels 
by postnatal day 60. DA content remains constant through 
adulthood and senescence. In contrast, DOPAC levels develop 
more rapidly than DA levels, attaining adult values by 20 
days after birth, a time when DA is less than 50% of adult 
level. DOPAC content remains unchanged through senescence. 
Basal AC activity increases 6-fold from birth to postnatal 
day 45. Concentration-response curves for DA-stimulated AC 
activity indicate that 100 uM DA induces a maximal
stimulation of cAMP in rats of different ages. The effect
of this concentration of DA increases 4-fold from birth to 
postnatal day 14 when the maximal responsiveness to DA is 
observed. The effectiveness of DA on AC production rapidly 
returns to adult levels thereafter. Striatal DA content 
reaches 50% of the adult value by postnatal day 35 (Giorgi 
et al., 1987). DA content of the brain rises significantly 
between 0-7 days after birth, with the greatest rise per 
unit time occuring between 7 and 18 days. Adult levels are 
attained at about 50 days. The most rapid increase in TH
activity is between the 7th and 18th day.
The above findings indicate that DA-containing neurons 
gradually develop their functions during fetal life and the 
first 4-8 weeks of postnatal life.
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Ontogeny of Dopamine D1 Receptors 
The density of DA D1 receptors in rat striatum is only 
9% of the adult value at birth and increases very rapidly 
thereafter, so that by postnatal day 35 a peak value is 
attained (Giorgi et al., 1987). The maturation of DA D1 
receptors and DA-stimulated AC activity in the striatum (and 
other brain areas) precedes that of the presynaptic 
dopaminergic neuron markers (Spano et al., 1976; Hohn and 
Wuttke, 1979; Lamberts and tfuttke, 1981; Giorgi et al., 
1987). DA D1 receptors increase in density more rapidly 
than DA D2 receptors in the first two weeks postnatally.
The ratio of D1 to D2 receptors increases from 1.7 at 2 days 
of age to 3.3 at 14 days of age (Zeng et al., 1988).
Ontogeny of Dopamine D2 Receptor 
In vivo and in vitro studies have shown that DA D2 
receptors double in number between day 5 and day 15 after 
birth, and then gradually increase to adult levels by day 30 
(Pardo et al., 1977; Murrin, 1982; Murrin and Zeng, 1986). 
Since DA plays an important trophic role in the development 
of a normal number of striatal DA receptors (Rosengarten et 
al., 1983a; Miller and Friedhoff, 1986), it has been 
suggested that the development of DA D2 receptors, and the 
responses that they mediate, are dependent upon the 
maturation of their corresponding presynaptic nerve 
terminals (Rosengarten and Friedhoff, 1979; Deskin et al.,
1981). Some reports do not support this view (Creese and 
Iversen, 1973; Pardo et al., 1977). Striatal presynaptic 
receptors, which are D2 receptors, may be just starting to 
function around the first week of life and may not attain 
full maturity until the second postnatal week (Shalaby et 
al., 1981).
Impairment_Of^Popamine Receptor Ontogeny
Rosengarten and Friedhoff (1979) found that prenatal 
administration of haloperidol results in a persistent 
decrease in postnatal striatal DA D2 receptors (Rosengarten 
et al., 1983b), The critical period for this prenatal 
neuroleptic effect is between gestational days 15 and IB 
(Rosengarten et al., 1983a). This treatment also affects 
muscarinic cholinergic activity in the striatum (increase in 
binding sites) (Miller and Friedhoff, 1986). On the other 
hand, giving haloperidol to nursing dams for the first 21 
days after birth, results in a 40ft increase in the number of 
striatal DA D2 receptors in the nursing littermates, two 
weeks after the last dose (Rosengarten and Friedhoff, 1979). 
Treatment of neonatal rats with penfluridol, on alternate 
days during the first postnatal week, does not affect the 
development of striatal DA D2 receptors, although there is a 
supersensitive response of these rats to the DA receptor 
agonist, apomorphine (Coyle et al., 1981).
Kostrzewa and Saleh (1989) have shown that
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administration of the DA D1 receptor antagonist, SCH 23390 
(0.3 mg/kg i.p.), or the DA D2 receptor antagonist, 
spiroperidol (1.0 mg/kg i.p.), to rats once a day for 32 
successive days from birth results in a marked impairment of 
the development of striatal D1 receptors at 12 weeks (74% 
reduction in the specific binding) and marked impairment of 
the development of striatal D2 receptors at 12 weeks (74% 
reduction in the specific binding), respectively.
It can be conclude from the above results that the 
fetal and early postnatal periods in rats may be vulnerable 
stages in the functional maturation of the central 
dopaminergic system. Investigation of the development of 
this system might assist in understanding its physiological 
significance.
Dopaminergic System and Behavior 
Animal behavioral assays are an important tool for 
elucidating actions of drugs used in the treatment of CNS 
disorders. The behavioral assays have been used to define 
the characteristic profiles of DA antagonists and DA 
agonists, in the hope of screening new drugs for therapeutic 
value. The behavioral assays used most commonly are as 
follows:
1. The rotational model, which usually includes 
unilateral 6-OHDA lesions of the substantia nigra 
or of the median forebrain bundle of rats. A
contralateral circling response (away from the 
lesioned side) is produced by DA agonists which 
preferentially stimulate supersensitive DA 
receptors on the denervated side. Conversely, an 
ipsilateral circling response is produced by 
dopaminomimetics which release DA from intact 
dopamine neurons on the non-lesioned side, 
resulting in postsynaptic stimulation of DA 
receptors on the intact side.
2. The stereotypy model, which includes 
observation of such behaviors as licking, gnawing, 
biting, chewing (oral stereotypy), sniffing, 
rearing, grooming, and locomotion in rats.
3. The catalepsy model is best described as a loss 
of locomotor behavior and an exaggeration of 
bracing responses to stimuli. This categorization 
is operationally defined, for example, by placing 
a rat's forepaws over a horizontal bar and 
observing time of immobility in the imposed 
posture. Catalepsy results from blockade of DA D1 
and/or D2 receptors in the striatum. It is known 
that these receptive site are restricted to 
quinolinic acid-sensitive intrinsic neurons 
(Calderon et al., 1988).
4. The yawning response, which is elicited in 
experimental animals by DA agonists. This effect
is antagonized by the centrally acting DA 
antagonists. The receptors involved in this 
behavior have characteristics in common with the 
DA D2 autoreceptor (Mogilnicka and Klimek, 1977; 
Nickolson and Berendsen, 1980; Yamada and 
Furukawa, 1980; Gower et al.r 1984; Stable and 
Ungerstedt, 1984; Serra et at., 1983a,b; 1984; 
Dourish and Hutson, 1985; Yamada et al., 1986; 
Stoessl et al., 1987). However, according to some 
studies these receptors are located 
postsynaptically (Serra et al., 1986). 
Nevertheless, 6-OHDA lesions of DA neurons abolish 
the yawning response (Dourish and Hutson, 1985; 
Stoessl et al., 1987).
5. Perioral movements (abnormal mouth movements = 
oral dyskinesia). In humans, repetitious opening 
and closing of the mouth and high frequency clonic 
jaw movements are the most outstanding 
characteristic of tardive dyskinesia which results 
from prolonged neuroleptic treatment. Perioral 
movements in normal rats can be induced by 
selective stimulation of the DA D1 receptors or by 
selective blockade of D2 receptors with 
antagonists (Molloy et al,, 1986; Rosengarten et 
al., 1986; Koshikawa et al., 1987; Molloy and 
Waddington, 1988). Rats with reduced numbers of
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D2 receptors, resulting from strain difference, 
senescence, or pharmacological intervention in 
development demonstrate increased oral activity 
after D1 agonist treatment (Rosengarten et al.,
1983c; 1986). Oral behavior is increased in rats 
treated chronically with several neuroleptics 
(Clow et al., 1979; Waddington and Gamble, 1980; 
Waddington et al., 1981). The incidence of oral 
activity is least when DA D2 as well as DA D1 
receptors are stimulated (Rosengarten et al.,
1986; Johansson et al., 1987).
Heterogeneity of the Striatum 
The striatal internal organization of afferent and 
efferent projections is heterogeneous (Dray, 1979). The 
dorsal and ventral striatum are different in internal 
organization, embryonic origin, efferent and afferent 
projections (Joyce, 1983), and neurotransmitter content. 
More DA is present in the dorsal part and more 5-HT and 
norepinephrine are in the ventral part (Widmann and Sperk, 
1986).
Dopaminergic drugs injected into different regions of 
the striatum may interact with different elements of the 
striatum and produce diverse behavioral effects (Costal et 
al., 1980; Joyce et al., 1981). The dorsal rostral region 
supports the rearing response; a more caudal and medio-
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ventral region is involved in biting; and a rostro-ventral 
region sustains the hyperactivity response (Joyce, 1983). 
These findings emphasize the functional (behavioral) 
heterogeneity of the striatum (Dunnett et al., 1981a,b). 
After intraventricular 6-OHDA treatment, extensive loss of 
DA terminals occurs in medial portions of the striatum, 
while large numbers of terminals remain intact in more 
lateral areas (Onn et al., 1986).
Rationale
One factor that influences the clinical manifestation 
of any lesion in the CNS is the age of the brain at the time 
of the lesion. Although a lesion is static, its effect(s) 
on neurologic function is affected as the system matures. 
Since the striatum progresses through a prolonged and varied 
postnatal developmental period, DA receptor stimulation or 
blockade and/or dopaminergic fiber distruction during this 
interval is likely to alter development of receptor sites. 
The change may be quite different from that which is 
observed after a similar lesion in the adult.
Several drugs and neurotoxins administered to 
developing rats produce different biological consequences 
from those observed in adults. Chronic treatment of mature 
animals with neuroleptics leads to DA D2 receptor 
proliferation (Neve et al., 1985). Once the neuroleptic is 
withdrawn, the numbers of D2 receptors return to control
levels in a matter of days. However, when the dopaminergic 
system is altered during early development with prenatal 
treatment with DA D2 antagonists (Rosengarten and Friedhoff, 
1979), or postnatal treatment with DA D1 or D2 specific 
antagonists (Kostrzewa and Saleh, 1989), DA receptor down- 
regulation is observed. The changes in the system are 
permanent, persisting through adulthood.
Breese et al. (1984) demonstrated that the behavioral 
responses to DA agonists are distinctly different in 
neonatal and adult 6-OHDA-lesioned rats. Other differences 
between adult and neonatal 6-OHDA-lesioned rats have also 
been described. Rats treated with the neurotoxin as adults 
exhibit a profound aphagia, adipsia, and akinesia (Zigmond 
and Strieker, 1973). In contrast, after neonatal 6-OHDA 
treatment, rats do not display such an acute behavioral 
syndrome (Duncan et al., 1987). Also, neonatal destruction 
of brain dopaminergic neurons with 6-OHDA results in a 
selective supersensitivity of D1 receptors in the absence of 
an altered number of receptors (Breese et al., 1984,
1985a,b, 1986). Whereas neonatal 6-OHDA-lesioned rats show 
a greater response to D1 receptor agonists than to D2 
receptor agonists, adult 6-OHDA-lesioned rats show a greater 
sensitivity to D2 receptor agonists than to D1 agonists 
(Breese et al., 1985b). Chronic treatment with the specific 
DA D1 antagonist, SCH 23390, or DA D2 antagonist, 
haloperidol, produces a significant elevation in [3H]SCH
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23390 or [3H]spiroperidol binding, respectively, in 
unlesioned and in 6-OHDA adult-lesioned rats. The same 
chronic treatment in adult animals that were lesioned as 
neonates with 6-OHDA did not result in an up-regulation of 
the respective receptors (Duncan et al,, 1987).
Several measures of dopaminergic function in striatum 
and other brain areas are reduced in patients with Lesch- 
Nyhan syndrome, a disease associated with an inborn 
deficiency of the enzyme hypoxanthine-guanine phosphoribosyl 
transferase. Parkinson's disease is another syndrome in 
which brain dopamine is reduced. However, Parkinson's 
patients display tremor, bradykinesia, stiffness, and do not 
demonstrate the choreoathetoid movements, hypertonicity, the 
unique compulsive self-mutilation behavior (SMB) of digits 
and tissue about the mouth, or the elevation in serotonin in 
the striatum observed in children with Lesch-Nyhan disease. 
Apparent differences in these syndromes are the age of onset 
of the symptoms (the age at which dopaminergic pathways are 
destroyed) and the disordered purine metabolism in Lesch- 
Nyhan patients.
The adult 6-OHDA-treated rats has been used as a 
neurochemical model of Parkinson's disease. Breese et al. 
(1984; 1984a) have suggested that the neonatal 6-OHDA- 
treated rat may serve as a model of central dysfunctions 
observed in childhood diseases with reduced brain dopamine. 
Lesch-Nyhan syndrome is one of those diseases.
Dopamine D2 agonists are useful in Parkinsonism and do 
not appear to initiate self-mutilation behavior in rats 
treated neonatally with 6-OHDA (Breese et al., 1985a). It 
is not known whether administration of the D2 agonist would 
be beneficial to the motor dysfunction in the Lesch-Nyhan 
syndrome, or would exacerbate the choreic symptoms as 
observed with L-dopa in Huntington's chorea (Breese et al., 
1985a). One goal of the present experiment was to shed 
light on this important clinical question.
Agonist-induced behavioral supersensitivity has served 
as the standard animal model for certain of the motor and 
behavioral side effects associated with long-term exposure 
to DA agonists in humans. Its pharmacologic mechanism, 
however, remains unclear (Braun and Chase, 1988). In order 
to examine the relative contribution of D1 and D2 receptor- 
mediated mechanisms to the behavioral changes which follow 
chronic dopamine agonist exposure, either the R-enantiomer 
of SKF 38393 {2,3,4,5-tetrahydro-7,8-dihydroxy-l-phenyl-lH- 
3-benzazepine), the most selective, partial D1 agonist, 
(Pendleton et al., 1978; Setler et al., 1978; Watling and 
Dowling, 1981; Sibley et al., 1982) or the selective, full 
D2 agoniBt, LY 171555, (trans-4-4a,5,6,7,8,8a,9-octahydro-5- 
propyl-lH-pyrazolo(3,4-g) quinoline.), the (-)isomer of LY 
141865 (Tsuruta et al., 1981; Gundlach et al., 1983; Stoof 
and Kebabian, 1984; Plantje1 et al., 1985} was administered 
alone or in combination with 6-OHDA to rats during the
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postnatal period. Following a drug-free interval, 
behavioral responses to the selective DA agonists were 
evaluated.
This study was undertaken with the objective of (1) 
assessing both striatal DA D1 and D2 receptors in rats after 
postnatal treatment with selective D1 or D2 agonists and 
antagonists alone and in combination with neonatal 6-OHDA 
treatment. Other aims were to determine whether the above 
treatments would (2) modify the ontogeny of the respective 
receptor populations in the striatum, (3) modulate the 
abnormal responses that occur following neonatal treatment 
with 6-OHDA, or (4) alter the behavioral response(s) to 
challenge doses of agonists or antagonists given in 
adulthood.
A comprehensive study of the dopaminergic system is 
needed in order to combine and compare the effects generated 
by 6-OHDA and the effects generated by specific agonists and 
antagonists on this system.
This study should lead to a better understanding of the 
dopaminergic system and better enable an animal model to be 
developed that can assist in the development of agents that 
can be useful in the treatment for DA receptor 
supersensitivity or subsensitivity caused by structural 
damage or functional alterations in the brain.
CHAPTER 2 
Materials and Methods
This project was divided into two parts. The first 
series of experiments were conducted to determine the effect 
of chronic stimulation with specific agonists on the 
ontogeny of DA D1 and D2 receptors. The second series of 
experiments were undertaken to test the ability of specific 
postnatal treatment with D1 or D2 agonists or antagonists to 
modulate the changes produced by neonatal 6-OHDA treatment.
An ima1sand ^Treatment
Timed pregnant Sprague-Dawley albino rats were obtained 
from Charles River Labs (Research Triangle Park, NC) about 1 
week before parturition, housed singly in plastic cages with 
food and water ad libitum, and were kept on a twelve hour 
light-dark cycle (on at 07:00 h) at 22+1 °C. Date of litter 
delivery was noted within 12 hours and the day of birth was 
considered day 0. At birth the pups from all litters were 
randomly assigned to the mothers, and litters were culled to 
a maximum of ten pups. All offspring used in the study were 
weighed once a day from birth until the end of treatment (32 
days of age).
Starting at birth, all neonates were treated once a day 
for 32 successive days by intraperitoneal (i.p.) injection
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with one of the following regimens: (a) saline (0,85ft) plus 
saline containing tartaric acid (0.5%) and acetic acid (1.0 
mM), (b) SCH 23390 HC1 (0.3 mg/kg, free base; Research 
Biochemicals, Inc., Natick, MA) in saline (0.85ft) plus 
saline-tartaric acid/acetic acid, (c) spiroperidol (0.3 
mg/kg, Research Biochemicals) in saline-tartaric acid/acetic 
acid plus saline, (d) SKP 38393 HC1 (3.0 mg/kg, Research
Biochemicals), or (e) LY 171555 HC1 (3.0 mg/kg, Lilly,
Research Labs, Indianapolis, IN). At 3 days after birth, 
groups of rats receiving the above treatment were treated 
with 6-OHDA hydrobromide (67.5 A? intracerebroventricular,
i.c.v., free base, in each side; Regis Chemical Co.,
Chicago, IL) or the diluent, saline (0.85ft) with ascorbic 
acid (0.1ft) to prevent the spontaneous oxidation of 6-OHDA. 
Rats were weaned at 4 weeks of age. At 38-41 days of age,
rats from all the above groups were challenged with the
specific DA D2 agonist, LY 171555, to study yawning 
behavior. At 44-47 or 49-51 days of age, rats were 
challenged with the DA D1 specific agonist, SKP 38393 (3.0 
mg/kg) or the DA D2 specific agonist, LY 171555 (3.0 mg/kg), 
respectively, to study stereotypic behaviors. At 70 days of 
age, rats were challenged with the DA D2 specific 
antagonist, spiroperidol (40 Ag/kg, i.p.), to study the oral 
dyskinesia.
For the binding studies, a separate group of rats 
untreated after 32 days was used. These rats were killed by
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decapitation at 55 to 57 days. Brains were immediately 
removed and the striata were dissected free, frozen on dry 
ice, and stored at -60 °C.
One rat treated with 6-OHDA did have post-decapitation 
convulsions and was not used for assessment of D1 or D2 
receptor number.
Tissue Preparation 
At the time of assay, parts of striata from the same 
medio-lateral and/or dorso-ventral location were placed in 
100 volumes of 50 mM Tris buffer (pH 7.4) containing 120 mM 
NaCl and 5 mM KC1. After homogenization (setting of 50, 20 
s; Tekmar Tissumizer), samples were centrifuged at 48,000 x 
g for 25 min at 4 °C in a Beckman L5-75B ultracentrifuge. 
This step was repeated after resuspending the pellets in 100 
volumes of fresh buffer. The final pellets were resuspended 
in the Tris-salt solution.
D1 Binding Assay 
To assess DA D1 receptor binding, the method of Schulz 
et al. (1985) was employed. Briefly, samples of 0.2 ml of 
homogenate were added to 0.1 ml [3H]SCH 23390 (50 to 1500 
pM, final conc.; Amersham, Monton Grave, IL) in Tris-salt 
solution containing 2 mM CaC12. Samples (1 ml incubation 
mix) were incubated for 15 min at 37 °C in a shaking water 
bath and then rapidly filtered under partial vacuum on
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Whatman GF/F glass fiber filters using a Millipore 
filtration unit. Filters were washed three times with 5 ml 
of ice-cold Tris-salt solution. After drying, filters were 
placed in 9 ml of Scintiverse £ (Fisher Scientific, Atlanta, 
GA), and tritium activity was determined in a Beckman LS 
9800 liquid scintillation spectrometer, specific binding of 
[3H]SCH 23390 was defined as the difference in binding in 
the presence and absence of SCH 23390 (1/tM).
D2 Binding Assay
To assess DA D2 receptor binding, the method of Creese 
and Snyder (1979) was used. Aliquots of homogenate (0,2 ml) 
were incubated with 0.1 ml [3H]spiroperidol (50 to 1500 pH, 
final conc.; Amersham) in Tris-salt solution containing 0.5 
mM MgC12. Samples (1 ml incubation mix) were incubated for 
15 min at 37 °C in a shaking water bath and then rapidly 
filtered under partial vacuum on Whatman GF/F glass fiber 
filters using a Millipore filtration unit. Filters were 
washed three times with 5 ml of ice-cold Tris-salt solution. 
After drying, filters were placed in 9 ml of Scintiverse E 
(Fisher Scientific), and tritium activity was determined. 
Specific binding of [3H]spiroperidol was defined as the 
difference in binding in the presence and absence of d- 
butaclamol (1/(M; Research Biochemicals, Inc.).
Since [3H]spiroperidol has been shown to bind to 
serotonin-2 receptors (S2) (Leysen et al., 1978; Pertoutka
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and Snyder, 1979; Witby et al., 1980; Witby et al., 1981}, 
ketanserin was added to block serotonin receptors (Murrin 
and Kuhar, 1979). Ketanserin, at a concentration of 27 nM, 
selectively binds to S2 sites allowing specific study of the 
D2 receptors (Leysen et al., 1981; 1982; Hamblin et al., 
1984)..
Equilibrium Binding Studies
In order to determine the maximal binding capacity 
(Bmax) and the apparent dissociation constant (Kd) for 
[3H]SCH 23390 and [3H]spiroperidol receptor binding, a 
double rectangular hyperbola model was used. This describes 
the interaction of a selective radioligand with two classes 
of non-interacting binding sites {B = (Bmaxl)(L)/(L+Kdl) +
(Bmax2)(L)/{L+Kd2} + EL}, where B is the amount of 
radioligand bound, Bmaxl and Bmax2 are the densities of the 
two classes of binding sites, L is the free concentration of 
radioligand, Kdl and Kd2 are the dissociation constants of 
the binding sites for the radioligand, and E is the ratio of 
non-specific binding siteB at the L concentration. Since 
the data could be fit by a single site model and since there 
was no significant improvement in fitting provided by a two 
site model, the Bmax2 was considered to be zero.
For [3H]SCH 23390 kinetic studies in rat striata, the 
[3H]SCH 23390 concentrations ranged from 50 to 1500 pM (8 
concentrations, total}.
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For [3H]spiroperidol kinetic studies in rat striata, 
the [3H]spiroperidol concentrations ranged from 50 to 1500 
pH (8 concentrations, total).
Behavioral Methods 
In all behavioral studies rats were placed in separate 
cages and were allowed to accommodate to the behavioral 
testing laboratory for one hour prior to drug treatments.
To avoid possible circadian effects, behavioral observations 
were conducted at the same time each day for the different 
tests.
1. Yawning. Yawning was studied by administering a 
challenge dose of the DA D2 specific agonist, LY 
171555 (50 /lg/kg, i.p.; Serra et al., 1987). Rats 
were then placed in small Perspex observation 
cages (48 x 26 x 18 cm) and observed individually. 
Starting 5 min after LY 171555 injection, the 
following behavior elements were scored over the 
next 25 min: a) number of yawns, b) number of 
penile erections, and c) duration of genital 
grooming. These sessions were carried out between 
09:00 and 14:00 hr. in a quiet, well-lighted room.
2. Oral Dyskinesia. Oral dyskinesia (spontaneous 
chewing jaw movements) were assessed by 
administering a challenge dose of the specific DA 
D2 antagonist, spiroperidol (40 Ag/kg, i.p.)
(Laduron et al., 1978; Leysen et al., 1978). One 
hour after spiroperidol treatment, the numbers of 
oral movements were recorded for 1 min every 10 
min for 6 periods (Rosengarten et al., 1983;
1986). Chewing was recorded only if it appeared 
to be purposeless, that is, if it was not directed 
at any specific object.
3. Stereotypic Behavior. Behavioral observations 
were made as has been described by Breese et al. 
(1984; 1985a,b). Following a 60 min adaptation 
period in clear Perspex cages (48 x 26 x 18 cm) 
with wood chip bedding on the floor, drugs were 
administered. Behavioral assessment was made for 
a 1 min period once every 10 min for 90 min. Each 
min was divided into four 15 s periods and 
behaviors were scored as occurring or not 
occurring during each 15 s period. Therefore, the 
maximum score for any observed behavior in a 1 min 
period was 4 (i.e., once in each 15 sec interval). 
The behaviors observed were locomotion, rearing 
(both front legs off the floor of the cage), 
licking, sniffing (intense 8-10/sec directed 
towards the sides or floor of the observation 
cage), taffy pulling (coordinated movement of 
front paws toward the mouth and then away from the 
body), head nodding (head moving up-and-down or
37
side-to-side in a repetitive fashion), paw 
treading, jumping, digging, eating wood chips, 
grooming, and self-biting.
Data Analysis
Binding studies
The means of Bmax and Kd values in different groups 
were analyzed by the analysis of variance (ANOVA) followed 
by a post-ANOVA Newman-Keuls test, in order to test for 
significant differences between the treatment groups. A p 
value of <0.05 was considered to be the level for 
statistical significance.
Yawning and Oral Dyskinesia
The results were expressed as the mean number of 
responses per group ± S.E.M. to give an indication of 
variability. The statistical significance of the results 
was evaluated by the analysis of variance (ANOVA) followed 
by a post-ANOVA Newman-Keuls test, A p value of <0.05 was 
considered to be the level for statistical significance.
Stereotypic Behavior
Data are expressed as the mean total stereotypy score 
for 90 min + S.E.M to give an indication of variability.
The statistical significance of the results was evaluated by
the analysis of variance (ANOVA) followed by a post-ANOVA 
Newman-Keuls test. A e  value of <0.05 was considered to be 
the level for statistical significance.
CHAPTER 3 
Results
Enhanced Yawning Response to the DA P2 Specific Agonist 
LY 171555 in Rats Treated During Development with
LY 171555
Rats treated daily during postnatal development with 
the D2 receptor agonist LY 171555 (3,0 mg/kg/d, i.p.) 
demonstrated an 89% increase in the number of yawns that 
were induced by a challenge dose of LY 171555 (50/fg/kg, 
i.p.). In rats that were tested at 38 to 41 days after 
birth, the incidence of LY 171555-induced yawning was 25.0 + 
3.9 during the 25 minute observation period vs. 13.2+2.9 
for that of the control group (p < 0.05, Figure 1 and Table
1). The yawning response rate for rats treated in 
development with spiroperidol (0.3 mg/kg/d, i.p.) was not 
different from control. When rats were treated neonatally 
with 6-OHDA (200 /(g, salt form, i.c.v.), the enhanced 
response of the LY 171555-treated group was eliminated. The 
yawning response to a challenge dose of LY 171555 was 
approximately 3 yawns during the observation period for both 
the diluent and LY 171555 groups. However, neonatal 6-OHDA 
treatment did not alter the number of yawns in the rats 
treated with spiroperidol in development (Table 1, Fig. 1). 
Treatment during development with SKF 38393 (3.0 mg/kg/d,
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i.p.) or SCH 23390 (0.3 mg/kg/d, i.p.) did not alter the 
yawning response to the challenge dose of LY 171555 when 
compared to the control.
The number of penile erections and the duration of 
genital grooming were not statistically different between 
the groups.
Enhanced Perioral Response to the DA D2 Specific Antagonist 
Spiroperidol in Neonatal 6-OHDA-Lesioned Rats 
Rats treated at 3 days after birth with 6-OHDA (200 
Jig/kg, salt form, i.c.v.) demonstrated a 710% (7-fold) 
increase in the number of clonic jaw movements that were 
induced by a challenge dose of spiroperidol (40/fg/kg, 
i.p.}. In rats tested at 70 days after birth, the incidence 
of spiroperidol-induced perioral movements (oral dyskinesia) 
was 45.4 ± 9.9 during the observation period (1 min every 10 
min for 6 times) vs. 5.6 + 2.0 for that of the control group 
(p < 0.05, Table 2, Figure 2). The clonic jaw response rate 
for rats treated in development with SCH 23390 (0.3 mg/kg/d, 
i.p.) or SHF 38393 (3.0 mg/kg/d, i.p.) alone was not 
different from control, but when combined with 6-OHDA, the 
enhanced response of the 6-OHDA-treated group was 
eliminated.
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Table 1
Effects of Acute LY 171555 (50 Xfe/kg, i.p.) on Yawning in Rats 
Treated During Development with Dopamine Agonists or Antagonists
Developmental
Treatment
No. Of Yawns No. Of Penile 
Erections
Duration Of Genital 
Grooming (sec)
VEHICLE +
DILUENT 13.2 + 2.9 1.4 ± 0.8 7.4 ± 4.8
LY171555 25.0 + 3.9*'l'e 2.2 ± 1.2 12.3 + 5.0
SPIPERONE 12.6 + 2.6 2.8 + 0.5 19.4 + 4.6
SCH23390 9.0 + 2.0 1.0 ± 0.4 8.3 + 3.4
SKF38393 12.6 ± 1.2 2.0 + 0.5 14.2 + 5.2
6-OHDA *
DILUENT 3.0 + 0.3 1.2 + 0.2 9.4 + 6.2
LY171555 3.3 + 1.0 0.8 + 0.8 5.0 + 4.1
SPIPERONE 14.8 + 3.1b 1.3 + 0.3 12.3 + 2.5
SCH23390 7.2 + 2.1 1.6 ± 0.8 15.6 + 8.2
SKF38393 1.3 + 0.3 0.3 + 0.3 3.3 + 3.3
Rats were treated i.p., daily from the day of birth to 32 
days after birth, with diluent, LY 171555 (3.0 mg/kg/d), 
spiroperidol (spiperone) (0.3 mg/kg/d), SCH 23390 (0.3 
mg/kg/d) or SKF 38393 (3.0 mg/kg/d). All rats were also 
treated i.c.v. at 3 days after birth with 6-OHDA (200 Mg, 
salt form) or diluent. At 38 to 41 d after birth, rats were 
challenged with LY 171555 (50 Mg/kg, i.p.), and the numbers 
of yawns and penile erections, and the duration of genital 
grooming were recorded for 25 min, beginning 5 min after 
acute LY 171555 treatment.
Each value represents the Mean ± S.E.M. for 5 rats.
a, e < 0.05, compared to the 'Vehicle + Diluent1 group.
b, p < 0.05, compared to the '6-OHDA + Diluent' group.
c, e < 0.05, compared to the 'LY 171555 + 6-OHDA' group.
42
35
30
c n  2 5  
z| 20 
°  15
O  
z  10
5
0 1
DILUENT 6-OHDA
IC.V. TREATMENT
Figure 1. Effects of Acute LY 171555 (50/fg/kg, i.p.) on 
Yawning in Rats Treated During Development with Dopamine 
Agonists or Antagonists. Rats were treated i.p., daily from 
the day of birth to 32 days after birth, with diluent, LY 
171555 (3.0 mg/kg/d) or spiroperidol (0.3 mg/kg/d). All rats 
were also treated i.c.v. at 3 days after birth with 6-OHDA 
(200 /(g, salt form) or diluent. At 38 to 41 d after birth, 
rats were challenged with LY 171555 (50/fg/kg, i.p.), and 
the numbers of yawns was recorded for 25 min, beginning 5 
min after acute LY 171555 treatment.
Each value represents the Mean ± S.E.M. for 5 rats.
a, p < 0,05, compared to the 'Vehicle + Diluent* group.
b, jj < 0.05, compared to the '6-OHDA + Diluent* group.
c, p < 0.05, compared to the 'LY 171555 + 6-OHDA* group.
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Table 2
Effects of Acute Spiroperidol (40 Jtg/kgt i.p.) on the Incidence 
of Perioral Movements in Neonatal 6-OHDA-Lesioned Rats
Developmental
Treatment No. Of Repetitive Jaw Movements
VEHICLE +
DILUENT 5.6 ± 2.0
SCH23390 4.8 + 3.1
SKF38393 3.4 ± 0.9
6-OHDA +
DILUENT 45.4 ± 9.9*
SCH23390 14.0 + 3.9*
SKF38393 3.0 + 1.7*
Rats were treated i.p., daily for the first 32 days from 
birth, with diluent, SCH 23390 (0.3 mg/kg/d), or SKF 38393 
(3.0 mg/kg/d), in combination with i.c.v. 6-OHDA (200>«g, 
salt form) or its diluent at 3 days of age. Animals were 
challenged with spiroperidol (40 /fg/kg, i.p.) at 70 days 
from birth, and were observed one hour after the challenge 
dose. Numbers of episodes of mouth movements (consisting of 
bursts of repetitive jaw movements) were summed over 6 one 
min periods, separated by 10 min intervals.
Results are expressed as the Mean + S.E.M. for 5 rats.
a, e < 0.05, compared to the 'Vehicle + Diluent' group.
b, e < 0,05, compared to the '6-OHDA + Diluent1 group.
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Figure 2. Effects of Acute Spiroperidol (40/fg/kg, i.p.) on 
the Incidence of Perioral Movements in Neonatal 6-OHDA- 
Lesioned Rats. Rats were treated i.p., daily for the first 
32 days from birth, with diluent or SKF 38393 (3.0 mg/kg/d), 
in combination with i.c.v. 6-OHDA (200/lg, salt form), or 
its diluent at 3 days of age. Animals were challenged with 
spiroperidol (40><fg/kg, i.p.) at 70 days from birth or SKF 
38393 (3.0 mg/kg, i.p.) at 77 days from birth, and were 
observed one hour after the challenge dose. Numbers of 
episodes of mouth movements (consisting of bursts of 
repetitive jaw movements) were summed over 6 one min 
periods, separated by 10 min intervals.
Results are expressed as the Mean ± S.E.M. for 5 rats.
a, jp < 0.05, compared to the 'Vehicle + Diluent* group.
b, p < 0.05, compared to the '6-OHDA + Diluent' group.
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Enhanced Stereotypic Response to the DA D1 Specific Agonist 
SKF 38393 in Rats Treated Purina Development.with 
both SKF 38393 and 6-OHDA 
Daily treatment of rats during postnatal development 
with the D1 receptor agonist SKF 38393 (3.0 mg/kg/d, i.p.) 
was not associated with remarkable changes in stereotypic 
responses to a challenge dose of SKF 38393 (3.0 mg/kg, i.p.) 
(Tables 3-6). The neonatal 6-OHDA-lesioned rats (200 Mg, 
salt form, i.c.v.) also showed no remarkable changes in 
stereotypic responses to a challenge dose of SKF 38393 
(Tables 3-6). In rats treated in development with both 6- 
OHDA and SKF 38393, there were marked changes in stereotypic 
responses to the challenge dose of SKF 38393 at 44 to 47 
days. In this latter group there was a marked statistically 
significant increase over control in the score for licking 
(24.0 +3.2 vs. 5,2 +2.1), grooming (15.6 + 4.4 vs. 3.4 ± 
1.6), locomotion (26.8+ 3.5 vs. 7.6 + 2.7), jumping (8.0 + 
4.6 vs. 0.0), taffy pulling (16.8 + 3.1 vs. 1.4 + 0.9), and 
paw treading (14.0 ± 3.3 vs. 2.2 + 1.3) (Tables 3-6 and 
Figures 3-8).
In the same group (SKF 38393 + 6-OHDA), the incidence 
of SKF 38393-induced sniffing, digging, gnawing, eating, 
rearing, head nodding, and self-biting was not different 
from that of the control group (Tables 3-6). A challenge 
dose of SKF 38393 at 44 to 47 days did not modify the above 
behaviors in rats treated in development with LY 171555 (3,0
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mg/kg/d), spiroperidol (0.3 mg/kg/d), or SCH 23390 (0.3 
mg/kg/d). Neonatal 6-OHDA (200 Mg, salt form, i.c.v., at 3 
days of age) did not modify the responses to SKF 38393 
challenge in these groups (Tables 3-6).
Stereotypic Responses to the DA D2 Specific Agonist 
LY 171555 in Rats Treated During Development 
with both SKF 38393 and 6-OHDA 
Daily treatment of rats with SKF 38393 (3.0 mg/kg/d, 
i.p.) during the postnatal development period was not 
associated with remarkable changes in stereotypic responses 
to a challenge dose of LY 171555 (3,0 mg/kg, i.p.) at 49 to 
51 days of age (Tables 7-10), The neonatal 6-OHDA-lesioned 
rats (200 M<3, salt form, i.c.v.) also showed no remarkable 
changes in stereotypic responses to a challenge dose of LY 
171555 (3.0 mg/kg, i.p.) (Tables 7-10), However, in rats 
treated in development with both 6-OHDA and SKF 38393, there 
were marked changes in stereotypic responses to a challenge 
dose of the DA D2 specific agonist, LY 171555 (3.0 mg/kg, 
i.p.). The challenge dose of LY 171555 produced a marked 
increase over control, in the score for licking (20.6 + 6.5 
vs, 0.2 + 0,2), grooming (20.0 ± 6.9 vs. 0.0), and digging 
(20.0 + 3.2 vs. 0.4 ± 0.2) (Tables 7,8 and Figures 3,4,9).
On the other hand, the challenge dose of LY 171555 reduced 
the score for gnawing (4.4 ± 1.5 vs. 23.6 + 1.3) in this 
same group (SKF 38393 + 6-OHDA) (Table 8 and Figure 10). In
the same group (SKF 38393 + 6-OHDA), the incidence of LY 
171555-induced sniffing, eating, locomotion, rearing, 
jumping, taffy pulling, paw treading, head nodding, and 
self-biting were not different from that of the control 
group (Tables 7-10). In rats treated i.p. from the day of 
birth to 32 days of age with spiroperidol (0.3 mg/kg/d) or 
SCH 23390 (0.3 mg/kg/d) and were challenged with LY 171555 
(3.0 mg/kg, i.p.), there was no change in the incidence of 
stereotypic behaviors at age 49 to 51 days. Also, 6-OHDA 
did not affect the incidence of stereotypies in these latter 
groups (Tables 7-10).
Stereotypic Responses to the DA D2 Specific Agonist 
LY 171555 in Rats Treated During Development 
with LY 171555. with or without Neonatal 6-OHDA
When rats treated daily during postnatal development 
with LY 171555 (3.0 mg/kg/d, i.p.) were challenged with an 
acute dose of LY 171555 (3.0 mg/kg, i.p.) at 49 to 51 days 
from birth, there was a marked increase in the score for 
eating behavior (15.0 + 4.2 vs. 4.6 ±2.3) compared to that 
for the diluent control (Figure 11 and Table 8). Hats co­
treated in development with LY 171555 and 6-OHDA had 
increased scores for digging behavior (15.2 +6.2 vs. 0.4+
0.2 for the control), in response to the challenge dose of 
LY 171555 (3.0 mg/kg, i.p.) (Figure 9), In the same group 
(LY 171555 + 6-OHDA), the incidence of LY 171555-induced
48
sniffing, licking, grooming, gnawing, eating, locomotion, 
rearing, jumping, taffy pulling, paw treading, head nodding, 
and self-biting was not different from the control group 
(Tables 7-10).
Development of Striatal D1 Receptors in Postnatallv-Treated
Pats
Administration of the DA D1 receptor agonist or 
antagonist to rats once a day for 32 successive days from 
birth had no effect on striatal DA D1 receptor number and D1 
receptor affinity at 8 weeks of age (Table 11). In the 
group of rats treated in development with SKF 38393 (3.0 
mg/kg/d, i.p.), the in vitro binding of [3H3SCH 23390 to 
striatal homogenates was not different from the control 
group (Bmax = 6.6 + 2.2 fmol/mg tissue and Kd = 240.3 +53.3 
pM vs. 19.1+6.8 and 416.8 + 101.5, respectively, for the 
diluent control group). Groups that were treated neonatally 
with 6-OHDA (200 Mg, i.c.v., at 3 days of age) showed no 
difference in binding parameters from control. £n vitro 
binding of [3H]SCH 23390 to striatal homogenates showed that 
the Bmax was 17.8 + 5.6 fmol/mg tissue and the Kd was 600.0 
+ 101.9 for the 6-OHDA group, vs. 19.1+6.8 and 416.8 + 
101.5, respectively, for the diluent control group (Table
11). Rats treated alone with 6-OHDA (200 /<g, i.c.v., at 3 
days of age), in combination with SKF 38393 (3.0 mg/kg/d,
i.p., for 32 days), or SCH 23390 (0.3 mg/kg/d, i.p., for 32
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days) also were not statistically different from the control 
group.
Development of Striatal P2 Receptors in Postnatally-Treated
Rats
When the DA D2 receptor agonist or antagonist was 
administered to rats once a day for 32 successive days from 
birth there was no effect on the development of striatal DA 
D2 receptors at 8 weeks of age (Table 12). In the group of 
rats treated chronically with LY 171555 (3.0 mg/kg/d, i.p.) 
the in vitro binding of [3H]spiroperidol to striatal 
homogenates was not different from that of the control group 
(Bmax = 14.2 ± 1,9 fmol/mg tissue and Kd = 57.5 ± 7.2 pM vs. 
15.9 + 2.0 and 73.3 + 5.4, respectively). Groups treated 
neonatally with 6-OHDA (200 Ag, i.c.v., at 3 days of age) 
showed no difference in binding parameters from the control. 
In vitro binding of [3H]spiroperidol to striatal homogenates 
showed that the Bmax was 20.0 + 2.1 fmol/mg tissue and the 
Kd was 74.8 + 5.3 in the 6-OHDA group, vs. 15.9 + 2.0 and 
73.3 ± 5.4, respectively, for the diluent control group 
(Table 12). In rats treated with 6-OHDA (200 /fg, i.c.v., at 
3 days of age), alone or in combination with LY 171555 (3.0 
mg/kg/d, i.p., for 32 days) or spiroperidol (0.3 mg/kg/d, 
i.p., for 32 days), the binding parameters for D2 receptors 
were not different from the control group.
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popamine_pl Receptor Equilibrium. Binding Studies
Dopamine D1 receptor equilibrium binding studies were 
performed on striatal tissue taken from similar parts of the 
striatum at 8 weeks.from birth. Rats were treated 
chronically with diluent, SKF 38393 (3.0 mg/kg/d, i.p,), or 
SCH 23390 {0.3 mg/kg/d, i.p.) in combination with 6-OHDA 
(200 yUg, i.c.v. at 3 days of age) or its diluent. It was 
found that these treatments did not alter the Bmax or the Kd 
vs. the diluent control group (Table 11).
Dopamine D2 Receptor Equilibrium Binding Studies 
Dopamine D2 receptor equilibrium binding studies were 
performed on striatal tissue taken from similar parts of the 
striatum at 8 weeks from birth. Rats were treated 
chronically with diluent, LY 171555 (3.0 mg/kg/d, i.p.), or 
spiroperidol (0.3 mg/kg/d, i.p.) in combination with 6-OHDA 
(200 /fg, i.c.v. at 3 days of age) or its diluent. It was 
found that these treatments did not alter the Bmax or the Kd 
vs. the diluent control group (Table 12).
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Table 3
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
!DEVELOPMENT] 
TREATMENT
kL | 
BEHAVIORAL SCORE \
i
iVEHICLE +
| DILUENT 
| SKF38393 
I LY171555 
! SCH23390 
! SPIPERONE
SNIFFING LICKING GROOMING |
i
24.2 + 4.3 
26.6 + 6.2
18.8 i- 2.0 
18.6 + 1.0
19.8 + 5.3
5.2 ± 2.1 
8.6 + 2.6
9.6 ± 2.5
6.6 + 1.6 
5.4 + 1.7
3.4 + 1.6 |
5.6 + 1.7 J
7.6 + 3.1 | 
6.0 + 1.6 |
3.6 + 1.6 |
|6-OHDA +
! DILUENT 
! SKF38393 
! LY171555 
! SCH23390 
! SPIPERONE
24.7 + 3.8
31.8 + 1,8
27.8 + 4.0
24.2 + 5.2
28.3 + 5.8
5.2 + 2.9
24.0 + 3.2i,',c'* 
2.4 + 1.0 
8.0 + 2.1
10.0 + 3.8
11
2.7 +1.6 | 
15.6 + 4.41’b'( ! 
2.0 + 0.6 | 
4.4 + 1.4 j
2.0 + 0.9 !
1»
Rats were treated i.p., daily for the first 32 days from 
birth, with diluent, SKF 38393 (3 mg/kg/d), LY 171555 (3 
mg/kg/d), SCH 23390 (0.3 mg/kg/d) or spiroperidol 
(spiperone) (0.3 mg/kg/d) in combination with i.c.v. 6-OHDA 
(200 JXg, salt form, at 3 days of age) or its diluent.
Animals were challenged with SKF 38393 (3 mg/kg, i.p.) at 
44-47 days from birth, and were observed, beginning 10 min 
after the challenge dose. Numbers of episodes of each 
stereotypic behavior were summed over 9 one min periods, 
separated by a 10 min interval. Each min was subdivided 
into 15 sec sessions, and a score of 1 was assigned if a rat 
demonstrated a particular behavior during this interval.
The maximum score for each min was 4. For the 90 min 
period, the maximum score was 36 for each behavior.
Results are expressed as the Mean ± S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent1 group that were
challenged with SKF 38393.
b, p < 0.05, compared to the corresponding control group.
c, e < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, e < 0.05, compared to the same treatment with different 
challenge.
e, e < 0.05, compared to 'Vehicle + Diluent1 group that were 
challenged with LY 171555.
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Table 4
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
DEVELOPMENT;
TREATMENT
\L
BEHAVIORAL SCORE
VEHICLE + 
DILUENT 
SKF38393 
LY171555 
SCH23390 
SPIPERONE
DIGGING GNAWING EATING
2.0 + 0.7 
2.8 + 1.2 
0.4 + 0.2 
1.8 + 0.4 
2.4 ± 0,7
8.0 + 0.8 
15.8 + 2.4 
8.0 + 1.9 
11.0 + 1.4 
6.2 + 1,4*
1.0 + 0.8 
2.6 + 1.1
1.0 ± 0.5 
0.4 + 0.4
2.0 + 1.1
6-OHDA + 
DILUENT 
SKF38393 
LY171555 
SCH23390 
SPIPERONE
2.5 + 1.6 
13.4 + 4.9* 
2.4 + 0.9 
2,8 + 0.8 
2.8 + 1.3
11.3 + 2.2
11.2 + 4.1 
6.0 + 2.4* 
8.4 + 2.4
12.3 + 5.1
1.5 + 1.2
1.2 + 0.4 
0.6 + 0.4
1.2 + 0.8
2.5 + 0.9
Legend as in Table 3
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Table 5
Behavioral Effects Induced by SKF 38393 (3.0 ms/kg, i.p.) in Rats
that Received Repeated Treatment with 01 and D2 Receptor Agonists
or Antagonists During Postnatal Development
DEVELOPMENT
TREATMENT
1L
BEHAVIORAL SCORE
VEHICLE + 
DILUENT 
SKF38393 
LY171555 
SCH23390 
SPIPERONE
LOCOMOTION REARING JUMPING
7.6 + 2.7 
12.4 ± 3.2 
3.0 + 0.8
5.8 + 2.4
5.8 + 2.3
8.0 + 3.4 
13.0 + 4.0
2.4 + 1.1 
3.6 + 1.4
3.4 + 1.4
0.0 ± 0.0 
0.2 + 0.2 
0.0 + 0.0 
0.0 + 0,0 
0.2 ± 0.2
6-OHDA + 
DILUENT 
SKF38393 
LY171555 
SCH2339D 
SPIPERONE
10.5 + 3.8
26.8 + 3.51 
16.2 + 6.1 
11.0 + 4.5
16.8 + 3.6
10.0 + 4.6
18.0 + 3.4
12.8 + 7.3
10.8 + 4.3
17.8 + 6.4
0.0 ± 0.0 
8.0 + 4.6**l't'd't j 
5.6 ± 3.7 
0.2 + 0.2 
0.3 + 0.3
Legend as in Table 3
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Table 6
Behavioral Effects Induced by SKF 38393 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
|DEVELOPMENT. 
ITREATMENT
\L
BEHAVIORAL SCORE
!VEHICLE +
! DILUENT 
| SKF38393 
I LY171555 
j SCH23390 
i SPIPERONE
TAFFY PULLING PAH TREADING HEAD NODDING
1.4 ± 0.9 
3.6 + 1.3
2.8 + 1.4
1.8 + 0.5
1.8 + 1.1
2.2 + 1.3 
2.0 + 1.1 
0.0 + 0.0 
0.8 ± 0.8 
0.0 + 0.0
3.6 ± 1.7
8.6 + 3.4 
6.0 + 1.1 
6.4 + 1.9
7.6 + 3.9
|6-OHDA +
! DILUENT 
I SKF38393 
! LY171555 
j SCH23390 
! SPIPERONE
2.2 + 1.4
16.8 + 3. iatb.c,d,e
1.2 + 0.5
4.0 + 1.3
1.0 + 0.7
8.0 + 3.6 
14.0 + 3.31,e,e
11.2 + 6.9
6.0 + 2.6 
9.8 + 3.9
5.0 ± 2.6
2.6 4 0.8
5.4 4 3.9 
9.8 4 3.5 
5.3 4 2.1
Legend as in Table 3
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Figure 3. Behavioral Effects Induced by SKF 38393 (3 mg/kg,
i.p.) in Rats that Received Repeated Treatment with D1 or D2 
Receptor Agonists During Postnatal Development. Rats were 
treated i.p., daily for the first 32 days from birth, with 
diluent, SKF 38393 (3 mg/kg/d), or LY 171555 (3 mg/kg/d) in 
combination with i.c.v. 6-OHDA (200/Cg, salt form, at 3 days 
of age) or its diluent. Animals were challenged with SKF 
38393 (3 mg/kg, i.p.) at 44-47 days from birth, and were 
observed, beginning 10 min after the challenge dose. Numbers 
of episodes of each stereotypic behavior were summed over 9 
one min periods, separated by a 10 min interval. Each min 
was subdivided into 15 sec sessions, and a score of 1 was 
assigned if a rat demonstrated a particular behavior during 
this interval. The maximum score for each min was 4. For the 
90 min period, the maximum score was 36 for each behavior. 
Results are expressed as the Mean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent* group that were 
challenged with SKF 38393.
b, jp < 0.05, compared to the corresponding control group.
c, d < 0.05, compared postnatal treatment with 6-OHDA vs. 
witnout 6-OHDA.
d, p < 0.05, compared to the same treatment with different 
challenge.
e, p < 0.05, compared to ’Vehicle + Diluent1 group that were 
challenged with LY 171555.
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Table 7
Behavioral Effects Induced by LY 171555 (3.0 ms/kg, i.p.) in Rats
that Received Repeated Treatment vith D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
[DEVELOPMENT; 
JTREATMENT
\L !
BEHAVIORAL SCORE [
1
[VEHICLE +
| DILUENT 
{ SKF38393 
[ LY171555 
SCH23390 
! SPIPERONE
SNIFFING LICKING GROOMING |
i■
31.0 + 1.7 
32.2 + 0.9 
32.6 + 1.3 
30.8 + 1.2 
29.4 ± 1.5
0.2 + 0.2 
0.2 + 0.2 
2.2 + 1.3 
0.4 + 0.2 
0.0 + 0.0
0.0 + 0.0 i
o.o + o.o ! 
1.2 + 1.2 | 
0.0 + 0.0 [
0.0 + 0.0 !
_________________ 1
!6-0HDA +
! DILUENT 
| SKF38393 
| LY171555 
! SCH23390 
| SPIPERONE
31.6 + 2.2
21.8 + 5.5 
34,0 + 0.8
26.8 + 3.3 
30.3 + 2.3
8.6 + 5.9 
20.6 + 6.5,,',C|t 
2.2 + 0.9 
3.8 ± 2.5 
4.5 + 2.0
r1
8.0 + 5.9 !
2o.o + 6.9*'b'e'e [ 
1.2 + 1.2 [ 
2.4 + 1.5 [
4.0 + 2.0 |
1... 1
Rats were treated i.p., daily for the first 32 days from 
birth, with diluent, SKF 38393 (3 mg/kg/d), LY 171555 (3 
mg/kg/d), SCH 23390 (0.3 mg/kg/d), or spiroperidol 
(spiperone) (0.3 mg/kg/d) in combination with i.c.v. 6-OHDA 
(200 Mg, salt form, at 3 days of age) or its diluent.
Animals were challenged with LY 171555 (3 mg/kg, i.p.) at 
49-51 days from birth, and were observed, beginning 10 min 
after the challenge dose. Numbers of episodes of each 
stereotypic behavior were summed over 9 one min periods, 
separated by a 10 min interval. Each min was subdivided 
into 15 sec sessions, and a score of 1 was assigned if a rat 
demonstrated a particular behavior during this interval.
The maximum score for each min was 4. For the 90 min 
period, the maximum score was 36 for each behavior.
Results are expressed as the Hean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent’ group that were
challenged with SKF 38393.
b, e  < 0.05, compared to the corresponding control group.
c, e < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, e < 0.05, compared to the same treatment with different 
challenge.
e, e < 0.05, compared to 'Vehicle + Diluent’ group that were 
challenged with LY 171555.
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Table 8
Behavioral Effects Induced by LY 171555 (3.0 us/kg, i.p.) in Hats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
{DEVELOPMENT;
{TREATMENT
4L { 
BEHAVIORAL SCORE {
i
{VEHICLE +
{ DILUENT 
{ SKF38393 
{ LY171555 
i SCH23390 
{ SPIPERONE
DIGGING GNAWING EATING {
11
0.4 + 0.2
6.2 + 2.4
4.6 + 1.4
5.6 + 2.6
2.2 + 2.2
23.6 + 1.3
23.6 + 4.6 
26.2 + 2.7*'d
26.0 + 3.5*
19.0 ± 6.1
4.6 + 2.3 { 
9.4 + 4.5 {
15.0 + 4.2*'l'd't |
9.6 + 2.3 |
14.0 ± 4.9*,d {
__________________ i
,'6-OHDA +
{ DILUENT 
! SKF38393 
{ LY171555 
{ SCH23390 
{ SPIPERONE
2.2 ± 1.0 
20.0 + 3.2l'i'tt* 
15.2 +
4.4 + 2.3 
8.0 + 4.5
19.4 + 2.3 
4.4 + 1.5* 
16.2 + 3.7
27.0 + 3.8*'d
23.0 + 5.8
i
4.2 4 2.1 {
1.0 4 0.8 {
5.6 ± 1.4 { 
10.4 ± 3.6 |
6.3 4 2.8 {
ii
Legend as in Table 7
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Table 9
Behavioral Effects Induced by LY 171555 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
|DEVELOPMENT, 
ITREATMENT
\L
BEHAVIORAL SCORE
{VEHICLE + 
j DILUENT 
! SKF38393 
! LY171555 
! SCH23390 
{ SPIPERONE
LOCOMOTION REARING JUMPING
15.2 ± 2.8
18.6 + 4.0
17.6 + 3.9
15.6 + 2.9
10.2 + 3.2
0.4 ± 0.2 
3.8 + 2.6 
2.6 + 1.9 
0.4 + 0.2 
4.4 + 2.2
0.4 ± 0.4 
0.2 ± 0.2 
0.0 + 0.0 
0.2 + 0.2 
0,6 + 0.6
J 6-OHDA +
| DILUENT 
! SKF38393 
I LY171555 
{ SCH23390 
! SPIPERONE
16.0 + 4.3 
8.8 + 2.9
23.8 + 4.4
14.0 + 4.2
13.8 + 2.3
4.8 + 3.8
7.0 + 2.7
3.6 + 2.2
5.6 + 4.2
2.0 + 1.2
0.0 ± 0.0 
0.0 ± 0.0 
0.2 + 0.2 
1.0 ± 1.0 
0.3 ± 0.3
Legend as in Table 7
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Table 10
Behavioral Effects Induced by LY 171555 (3.0 mg/kg, i.p.) in Rats
that Received Repeated Treatment with D1 and D2 Receptor Agonists
or Antagonists During Postnatal Development
[DEVELOPMENT;
[TREATMENT
\L [ 
BEHAVIORAL SCORE [
[VEHICLE +
[ DILUENT 
[ SKF38393 
[ LY171555 
[ SCH23390 
[ SPIPERONE
TAFFY PULLING PAW TREADING HEAD NODDING [
0.0 + 0,0 
0.0 ± 0.0 
0.0 + 0.0 
0.0 + 0.0 
0.0 + 0.0
0.0 + 0.0 
0.0 +
0.0 + 0.0 
0.0 ± 0.0 
0.0 + 0.0
1.4 + 0.6 [ 
1.0 + 0.6 [
2.2 + 1.4 [
1.2 ±0.5 [ 
0.6 + 0.2 [
[6-0HDA +
[ DILUENT 
[ SKF38393 
[ LY171555 
[ SCH23390 
[ SPIPERONE
0.0 + 0.0 
0.4 + 0,4 
0.0 + 0.0 
0.0 + 0.0 
0.0 + 0,0
1.6 + 1.0 
4.6 + 2.4 
0.2 + 0.2 
0.4 + 0.2 
0.0 + 0.0
0.8 + 0.8 [ 
0.4 + 0.2 [ 
2.2 + 2.2 [ 
0.4 ± 0.2 [ 
0.8 ± 0.8 [
Legend as in Table 7
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Figure 9. Behavioral Effects Induced by LY 171555 (3.0 
mg/kg, i.p.) in Rats that Received Repeated Treatment with 
D1 or 02 Receptor Agonists During Postnatal Development.
Rats were treated i.p,, daily for the first 32 days from 
birth, with diluent, SKF 38393 (3 mg/kg/d), or LY 171555 (3 
mg/kg/d) in combination with i.c.v. 6-OHDA (200/tg, salt 
form, at 3 days of age) or its diluent. Animals were 
challenged with LY 171555 (3 mg/kg, i.p.) at 49-51 days from
birth, and were observed, beginning 10 min after the
challenge dose. Numbers of episodes of each stereotypic
behavior were summed over 9 one min periods, separated by a
10 min interval. Each min was subdivided into 15 sec 
sessions, and a score of 1 was assigned if a rat 
demonstrated a particular behavior during this interval. The 
maximum score for each min was 4. For the 90 min period, the 
maximum score was 36 for each behavior.
Results are expressed as the Mean + S.E.M. for 5 rats.
a, p < 0.05, compared to 'Vehicle + Diluent' group that were
challenged with SKF 38393.
b, j? < 0.05, compared to the corresponding control group.
c, j> < 0.05, compared postnatal treatment with 6-OHDA vs.
without 6-OHDA.
d, p < 0.05, compared to the same treatment with different 
challenge,
e, p < 0.05, compared to 'Vehicle + Diluent* group that were 
challenged with LY 171555.
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Legend as in Figure 9.
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Table 11
Characteristics of Striatal D1 Receptors in Postnatally-Treated 
Rats, as Determined by Ip Vitro Binding of [3HJSCH 23390
Treatment
Bin ax 
(fmol/ms tissue)
Kd
(pM)
Vehicle +
Diluent 19.1 + 6.8 416.8 ± 101.5
SKP38393 6.6 ± 2.2 240.3 ± 53.3
SCH23390 15.9 + 3.8 466.4 + 79.6
6-OHDA +
Diluent 17.8 ± 5.6 600.6 + 101.9
SKF38393 10.7 ± 2.6 439.4 ± 63.5
SCH23390 10.2 ± 2.3 508.8 + 103.2
Each value is the Mean + S.E.M. of 5 tissues.
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Table 12
Characteristics of Striatal D2 Receptors in Postnatally-Treated 
Rats, as Determined by Ip Vitro Binding of [3H]spiroperidol
Treatment
Bmax 
(fmol/mg tissue)
Kd
(pM)
Vehicle +
Diluent 15.9 ± 2.0 73.3 + 5.4
LY171555 14.2 + 1.9 57.5 ± 7.2
Spiroperidol 26.0 + 2.3 96.0 + 8.1
6-OHDA +
Diluent 20.0 + 2.1 74.8 ± 5.3
LY171555 22.6 ± 4.9 104.7 + 16.5
Spiroperidol 27.6 + 4.1 100.7 ± 12.0
Each value is the Mean + S.E.M. of 5 tissues.
*
CHAPTER 4 
Discussion
Enhanced Yawning and Eating Responses to the DA D2 Specific 
Agonist LY 171555 in Rats Treated During 
Development with LY 171555 
Yawning behavior appeared to be a well-suited model to 
study the function of the dopaminergic system. It provided 
a functional means for evaluating potential new dopamine 
agonists. Yawning has been associated with agonist 
activation of DA D2 receptors (Nickolson and Berendsen,
1980; Yamada and Furukawa, 1980; Gower et al., 1984; Stahle 
and Ungerstedt, 1984; Serra et at., 1983a,b; 1984b). Low 
doses of DA agonists have been reported to reduce 
schizophrenic morbidity and symptoms of hyperkinetic 
disorders (see references in Stahle and Ungerstedt, 1989).
In view of these clinical findings, it is important to 
establish experimental models for effects of low doses of DA 
agonists and to elucidate the underlying pharmacological 
mechanisms. Yawning is one of the candidate behaviors.
Yawning is also of clinical interest since it has been 
reported that psychotics rarely yawn, and yawning is 
symptomatic in a wide range of CHS disorders such as brain 
lesions, tumors, hemorrhage, motion sickness, chorea, and 
encephalitis (see references in Laping and Ramirez, 1988).
70
71
Yawning is considered to be therapeutic in preventing post­
operative respiratory complications and in adjusting the air 
pressure in the middle ear (see references in Frovine et 
al., 1987).
It is now well accepted that yawning involves DA D2 
receptors, which have characteristics in common with the D2 
autoreceptor (Gower et al.f 1984). This hypothesis is 
mainly based on the observation that the minute doses of DA 
receptor agonists needed to produce yawning are within the 
same range as those needed to stimulate DA autoreceptors. 
Higher doses of DA agonists, which stimulate postsynaptic DA 
receptors as well, produce locomotor hyperactivity and 
stereotypy and suppress yawning. The presynaptic origin of 
the yawning response to DA agonists is further suggested by 
the fact that this behavior is abolished by bilateral 6- 
OHDA-induced denervation of the striatum (Dourish and 
Cooper, 1985) and olfactory tubercles (Protais et al.,
1983), and by the fact that yawning is elicited by DA 
agonists such as 3-(3-hydroxyphenyl)-N-n-propylpiperidine 
(3PPP) (Gower et al., 1984; Stahle and Ungerstedt, 1984) and 
TL-99 (Mogilnicka et al., 1984), which are considered to 
preferentially or selectively stimulate DA autoreceptors.
On the basis of these observations it has been proposed by 
various authors (Mogilnicka and Klimek, 1977; Nickolson and 
Berendsen, 1980; Yamada and Furukawa, 1980; Gower et al., 
1984; Stahle and Ungerstedt, 1984; Serra et at., 1983a,b;
1984b) that yawning is a behavioral consequence of DA 
autoreceptor-mediated inhibition of DA transmission. This 
hypothesis, however, has been challenged by the fact that 
yawning appears about 9 days postnatally, before maturation 
of presynaptic dopamine receptors (Arnt, 1987), and by the 
fact that DA agonist-induced yawning is not due to a 
decrease in the extracellular levels of DA (Stahle and 
Ungerstedt, 1989). DA agonists can induce yawning when DA 
neurotransmission is apparently enhanced (Stahle and 
Untgerstedt, 1989),
It has recently been proposed that DA agonists induce 
yawning by actions outside the striatum, namely by releasing 
oxytocin in the CNS, possibly in the paraventricular nucleus 
(PVN) of the hypothalamus. This nucleus contains the cell 
bodies of DA neurons of the A14 group which constitute the 
so-called incerto-hypothalamic DA system together with those
of the All and A13 groups. DA D2 receptors have been
identified in these regions (Argiolas et al., 1987; Melis et 
al., 1986; 1987).
Results of this study revealed that rats treated during 
postnatal development with the DA D2 agonist LY 171555
exhibited a marked increase in LY 171555-induced yawning at
5 to 6 weeks after birth. This enhanced behavioral response 
was not accompanied by an increased binding of 
[3H]spiroperidol to DA D2 receptors at 55-57 days from 
birth. It was not clear whether these results indicated
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that [3H]spiroperidol binds to a site (striatum) which did 
not represent the action of LY 171555 or whether other 
mechanisms (supersensitivity) were responsible for the 
enhanced responses of this DA D2 agonist in the LY 171555 
group of rats.
The yawning rate in the control group corresponded to 
that at the reported peak of the LY 171555 dose-response 
curve (Serra et al., 1987), while the yawning response rate 
in the LY 171555 group was greater than in any previous 
report, to the researchers knowledge, suggesting that the 
enhanced response was not a shift in the dose-response 
curve. These results suggested that LY 171555 treatment in 
development produced a supersensitive animal model for 
yawning behavior.
Yawning has been suggested as a behavior subserving 
arousal when attention is decreasing in front of a danger. 
Yawning might then indicate a low degree of arousal mediated 
by the activation of the most sensitive population of DA 
receptors. Further activation of DA transmission might 
progress to full arousal, exploratory behavior, and then to 
stereotyped sniffing, licking, and gnawing. This hypothesis 
offers a logical explanation for the fact that yawning and 
stereotypy are mutually exclusive. Namely, when the latter 
is elicited, the former is suppressed (Protais et al.,
1983). Here it was proposed that the DA D2 agonist LY 
171555 produced yawning by stimulating DA D2 receptors in
the PVN of the hypothalamus which may represent the most 
sensitive group of D2 receptors* Greater stimulation by the 
agonist or increased sensitivity in the striatal DA 
receptors may lead to stimulation of the DA receptors in the 
striatum or activation of these receptors even with the same 
degree of the stimulus, respectively. Neonatal 6-0HDA- 
lesioned rats demonstrate a supersensitivity to DA D1 
agonists (Breese et al., 1984; 1985a,b; 1986). Furthermore, 
supersensitivity can be primed (increased) by repeated 
administration of specific DA D1 agonist SKF 38393, Those 
observations seem to be in accord with the low number of 
yawns that was observed in the group treated with 6-OHDA 
plus SKF 38393.
Dopaminergic mechanisms may be involved in the 
regulation of feeding behavior. Electrical stimulation of 
the lateral hypothalamus can elicit feeding in food-satiated 
animals. This stimulation-induced feeding is disrupted by 
neuroleptic treatment (Streather and Bozarth, 1987). 
Selective DA D2 receptor antagonists decrease the sham 
intake of sucrose in food-deprived rats (Schneider et al.,
1986), DA D2 receptor-selective agonists increase 
consumption of food pellets in rats (solid diets) which are 
blocked by D2 antagonists or by D1 antagonists, while a D1 
receptor selective agonist SKF 38393 decreases intake and 
produces anorexia (Martin-Iversen and Dourish, 1988).
Yawning, as mentioned, is considered a behavior
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subserving arousal when attention is decreasing in front of 
a danger, so it might be considered to indicate a low degree 
of arousal, mediated by the activation of the most sensitive 
population of DA receptors. On the other hand, stress- or 
stimulation-induced eating could reflect a general "arousal" 
effect with specific behaviors determined by salient 
environmental stimuli (Martin-Iversen and Dourish, 1988).
Results of this study showed that rats treated during 
postnatal development with a DA D2 agonist LY 171555 
exhibited a marked increase in LY 171555-induced eating at 7 
weeks after birth. This enhanced behavioral response was 
not accompanied by an increased binding of [3H]spiroperidol 
to DA D2 receptors at 7-8 weeks from birth. It was not 
clear if these results were suggesting that [3H]spiroperidol 
is binding to a site (striatum) which did not represent the 
action of LY 171555 to elicit eating or whether other 
mechanisms (supersensitivity) were responsible for the 
enhanced responses of this DA D2 agonist in LY 171555 
treated rats.
In conclusion, because of the fact that both yawning 
and eating behaviors were enhanced in the group that was 
treated during the postnatal period with a specific DA D2 
agonist LY 171555 and because these behaviors reflected a 
degree of "arousal," it was suggested that D2 agonist 
treatment during development produced a supersensitivity or 
a change in number of DA D2 receptors which mediated these
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behaviors. Further studies are needed to determine the 
relationship between these behaviors and the numbers of DA 
D2 receptors in the hypothalamus and to determine the 
possible usefulness of D2 agonist-treated rats as models to 
study mechanisms associated with eating behavior.
Enhanced Perioral Response to the DA D2 Specific Antagonist 
Spiroperidol in Neonatal 6-OHDA-Lesioned Rats 
Oral dyskinesia represent an excess number of 
involuntary perioral movements. This behavior appears with 
increasing frequency during continued stable therapy in 
Parkinsonian patients, perhaps reflecting increasing 
denervation supersensitivity of DA receptors (Marsden,
1982}. Oral dyskinesia, the most outstanding characteristic 
of tardive dyskinesia (TD), is observed in rats treated 
chronically with several neuroleptics (Clow et al., 1979a,b; 
Waddington and Gamble, 1980; Waddington et al., 1981).
These movements are most pronounced when DA D1 receptors are 
stimulated or when DA D2 receptors are inhibited (Holloy et 
al., 1986; Rosengarten et al., 1986; Koshikawa et al., 1987; 
Molloy and Waddington, 1988) or reduced in number following 
prenatal drug intervention, strain difference, or in 
senescence (Rosengarten et al., 1983c; 1986). When DA D2 as 
well as DA D1 receptors are stimulated, these movements are 
least prominent (Rosengarten et al., 1986; Johansson et al.,
1987), an observation that may prove relevant to the
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treatment of TD and Tourette's syndrome. These movements 
can be suppressed by the selective DA D1 antagonist SCH 
23390 or the cholecystokinin octapeptide (Stoessl et al., 
1989). The molecular and/or neural mechanism(s) involved in 
the receptor modulation in TD are unknown.
An important finding in the present study was that 
perioral movements could be produced in neonatal 6-OHDA- 
treated rats in high frequency when a very low dose of the 
DA D2 antagonist spiroperidol was administered. This animal 
model might be of importance for studying mechanisms 
involved in the mediation of oral dyskinesia in humans.
The availability of this neurochemical model with 
increased susceptibility for perioral movements may permit 
screening of a variety of pharmacological agents that could 
minimize the TD syndrome observed after long-term 
neuroleptic administration. The demonstration that neonatal 
6-OHDA-treated rats have D1 dominance (supersensitivity) 
without alteration in the number of binding sites vitro 
for [3H]SCH 23390 and [3H]spiroperidol to striatal 
homogenates is compatible with the findings of Breese and 
co-workers (1984, 1985a, 1986, 1987; Duncan et al., 1987). 
The findings in this study suggested that the mechanisms 
involved in this disorder were at a site beyond the receptor 
complex. It has been suggested that clinical 
psychopathological disorders in humans, such as 
schizophrenia and TD, represent conditions in which the
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defect is a developmental or drug-induced permanently 
altered state. With the ability of neonatal 6-OHDA-lesions 
to produce permanent effects on the dopaminergic system, it 
can be seen that the present behavioral model might more 
closely reflect the clinical situation. Future 
investigations in the neonatal 6-OHDA-treated rats will test 
the usefulness of this proposed model.
Enhanced Stereotypic Response to the DA D1 or D2 Specific 
Agonists SKF 38393 or LY 171555 in Rats Treated 
During Development with both SKF 38393 and 6-OHDA 
The study of animal behaviors induced by centrally- 
acting dopaminergic agents is a classical means of 
investigating the pharmacology of the DA system and the 
pathophysiology of human neuropsychiatric diseases. So it 
was sought first to characterize the behavioral consequences 
of independent D1 receptor stimulation in rats with an 
intact dopaminergic system and other rats with a 6-OHDA 
lesioned-system.
Following neonatal, but not adult 6-OHDA lesions, rats 
exhibit greater behavioral supersensitivity to a DA D1 
agonists than to DA D2 agonists (Breese et al., 1985a,b, 
1986). The sensitivity of DA D1 receptors increases with 
repeated exposure to a DA agonist in the neonatally 6-OHDA- 
treated rats (priming). Supersensitivity to DA agonists 
develops during the first days after denervation and reaches
a steady state depending on the number of treatments, the 
dose of drug used and the time after lesion. The priming is 
effective as a facilitatory factor for the expression of DA 
receptor supersensitivity and provides a mechanism for the 
strong enhancement of the effectiveness of the agonist or 
for making otherwise ineffective doses of agonist effective 
in producing an effect. The changes induced by the primer 
do not involve the DA receptor per se, and stimulation of DA 
receptors could trigger some changes in neurons located 
downstream from the DA receptor itself (Morelli et al., 
1989). This priming phenomenon has not been associated with 
DA D2 agonists (Breese et al., 1985b) and can be prevented 
by the D1 antagonist SCH 23390 (Criswell et al., 1989). The 
priming phenomenon, which appears to be permanent (Criswell 
et al,, 1989), suggests that DA D1 receptors may possess a 
degree of plasticity that could have important implications 
for understanding long-term changes in behavior associated 
with repeated drug use or the basis of symptoms of childhood 
disorders secondary to a central DA deficiency.
In this study priming of DA D1 receptor response was 
reflected by an increase in the frequency of several 
behaviors elicited by a challenge dose of the DA D1 agonist 
SKF 38390 including licking, grooming, locomotion, jumping, 
taffy pulling, and paw treading. Priming of DA D1 receptor 
responses was reflected by the increase in frequency of 
several behaviors elicited by a challenge dose of the DA D2
agonist LY 171555 including licking, grooming, and digging. 
While priming of the DA D2 receptor response has not been 
observed with repeated administration of the DA D2 agonist 
at weekly intervals (Criswell et al., 1989), this treatment 
results in priming of responses to the DA D1 agonist in 
neonatal 6-OHDA-lesioned rats (Criswell et al., 1989). 
Present results show that priming of the DA D2 receptor 
response is present and is reflected by an increase in the 
frequency of digging behavior elicited by a challenge dose 
of the DA D2 agonist LY 171555. At present, it is not known 
whether the time between treatments, the dose, and/or the 
length of the treatment are/is an important determinant of 
DA D2 receptor priming.
Although functional responses to SKF 38393 or LY 171555 
are enhanced in rats treated developmentally with SKF 38393 
or LY 171555 plus neonatal 6-OHDA, respective binding of 
[3H]SCH 23390 or [3H]spiroperidol to striatal membranes from 
these rats is not altered.
The absence of an association between the enhancement 
of DA agonist-induced behavior and DA antagonist binding 
suggests that there are deficiencies in the present 
understanding of DA receptor mechanisms. Change(s) in the 
second or third messengers linked to these receptors or 
change(s) in systems modulating DA-mediated effects may 
explain this. It is evident, however, that if any prolonged 
treatment produces no change in the number of a receptor
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population, it cannot necessarily be concluded that there is 
no effect on the kinetics of the processes determining 
steady-state receptor levels (Norman et al., 1987). Future 
studies might investigate a molecular mechanism for the 
enhanced behavioral responses observed in the absence of 
changes in receptor number.
DA D1 receptors may play a role in the transition from 
levels of arousal associated with behavioral efficiency to 
states of hyperarousal associated with behavioral 
disorganization. At low levels of DA D1 receptor 
stimulation (i.e., that produced by endogenous DA), DA D2 
receptor activation elicits complex motor responses such as 
locomotion and exploratory activity which are part of the 
animal's endogenous behavioral repertoire. This is seen, 
for example, when normal animals are placed in a novel 
environment. These behaviors are purposeful, goal-oriented, 
and associated with efficient motor responsiveness to a 
variety of sensory stimuli (Braun et al., 1986). In 
contrast, higher levels of DA D1 receptor stimulation are 
associated with diminished responsiveness to environmental 
stimuli and in the appearance of stereotypic behaviors which 
represent fragmentation and purposeless repetition of 
elements of these same behaviors (Braun et al., 1986).
Acute mania, attention deficit disorders with hyperactivity 
in children, Lesch-Nyhan disease, Gilles de la Tourette 
syndrome, and certain types of schizophrenia have been
characterized as states of hyperarousal associated with 
attention deficits and behavioral disorganization. Priming 
of the DA D1 receptor responsiveness in the neonatal 6-OHDA- 
lesioned rat represents a model of a long-term change in 
neural function associated with repeated activation of a 
chemically defined receptor system. As such, the underlying 
neurochemical mechanisms that lead to this increased 
sensitivity may be representative of changes in other 
central processes requiring a "permanent" neural message 
(Criswell et al,, 1989).
CHAPTER 5 
Summary
The present investigation demonstrated the following:
1. The DA D2 agonist LY 171555, when given 
chronically to rats in the postnatal period, 
produced supersensitive behavioral responses, 
namely yawning and eating, when these rats were 
challenged as adults with the same D2 agonist.
2. [3H]SCH 23390 and [3H]spiroperidol binding to 
striatal tissue was not altered in rats treated in 
development with specific agonists or antagonists 
for the D1 and D2 receptors. A neonatal 6-OHDA 
lesion did not modify binding in any of the 
agonist- or antagonist-treated groups.
3. Neonatal 6-OHDA-lesioned rats may serve as a 
useful animal model of tardive dyskinesia.
4. The ability of DA D2 receptors to be primed, as 
demonstrated for the first time in this study, may 
provide a means for studying particular 
stereotypic behaviors in animals.
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